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ABSTRACT
THE ASSESSMENT OF OSTEOINDUCTIVITY OF HUMAN 
ALLOGRAFT DEMINERALIZED BONE MATRIX BY 
IN  VIVO AND IN  VITRO ASSAY MODELS.
Min Zhang
Old Dominion University and Eastern Virginia Medical School, 1996 
Director: Dr. Lloyd Wolfinbarger. Jr.
The osteoinductive potential (osteoinductivity) is a very important aspect of 
demineralized bone matrix (DBM) as a biomaterial. This study is directed at establishing 
qualitative and quantitative assays of the osteoinductivity of human DBM. Further 
aspects of this study include an assessment of the effects of the production process, 
matrix characterization, and donor related factors on osteoinductivity of the DBM.
Athymic mice were chosen as the animal model for use in the in vivo bioassay. 
Implantation of DBM in muscle pouches provided for much higher osteoinductivity 
(remineralization to 10% calcium) than subcutaneous site implantation (remineralization 
to 1.6% calcium). Histological observations revealed that new bone and bone marrow 
formed after four weeks of intramuscular implantation. In the in vivo dose-response 
studies, 20 mg of DBM provided for the highest levels of osteoinductivity.
Human periosteal cells (HPO/CB-MZOl) were chosen for the in vitro bioassays of 
the osteoinductivity of DBM. Both biochemical and histochemical studies revealed that 
the DBM can induce significantly higher alkaline phosphatase (ALP) activities when 
compared to DBM-free control flasks after four days of incubation. In the in vitro dose- 
response studies 5 and 10 mg of DBM produced the highest osteoinductivity.
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The study of the effect(s) of residual calcium on osteoinductivity revealed that 
nondemineralized bone matrix lacked significant osteoinductivity. As the residual 
calcium content decreased, the degree of remineralization produced by the bone matrix 
increased, reaching maximum remineralization when the residual calcium content of bone 
matrix approached 2%. At residual calcium levels below 2%, osteoinductivity of the 
DBM decreased. The study of the effect of particle size revealed that DBM particles less 
than 250 micron produced the lowest osteoinductivity among all size groups studied. 
Bone particles in the 500-710 micron size range provided for DBM with the highest 
osteoinductivity. The effect of donor age on osteoinductivity of DBM revealed that 
demineralized bone matrix from 16 to 60 year old donors provided for nearly equivalent 
levels of remineralization, all in excess of 7% calcium in DBM explants.
In summary, this study established and validated the in vivo and in vitro bioassays 
for the assessment of osteoinductivity of DBM. Further, the study investigated the 
relationships between osteoinductivity and the residual calcium content in the DBM, the 
relationship between the osteoinductivity and particle size, and the relationship between 
the osteoinductivity and donor age and gender. The study validated the biochemical 
assays used for the assessment of the osteoinductivity of DBM. The results provided 
scientific evidence for the standards to be applied to the bone demineralization process 
and donor.
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Bone, interconnected by joints, constitutes the skeletal system. The fundamental 
functions of bone are: 1) to provide structural support for the entire body, 2) to protect 
delicate tissue and organs, 3) production of blood cells, and 4) storage and supply of 
calcium. Bone density and strength, reaching a peak between 30 and 35 years of age, are 
attributed to an orderly calcification of the extracellular matrix. According to architectural 
arrangement, bone can be divided into dense or compact and spongy or cancellous bone. 
Compact bone is relatively solid, whereas cancellous bone resembles a network of bony 
shafts separated by marrow spaces. Bone structural integrity, hardness, and ability to 
withstand stress are attributed to the unique organization of organic and inorganic 
components in the extracellular matrix (Amenta, 1990). Mature bone consists of 
inorganic bone minerals deposited on a framework of organic support material. Inorganic 
components constitute 75% of the dry mass of the extracellular matrix. Eighty five 
percent of the mineral fraction of bone is composed of calcium phosphate, in the form of 
hydroxyapatite crystals (Ca10.(PO4)6 (OH)2) (Amenta, 1990). The other inorganic 
components include: calcium carbonate (10%) and a combined total of 5% calcium 
fluoride, magnesium fluoride, and several other ions, especially citrate, potassium, and 
sodium. The organic matrix of bone, called osteoid, is composed of type I collagen 
(95%) and noncollagen (5%). These noncollagen components are osteopontin,
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osteonectin, phosphoproteins, bone Gla protein and proteoglycans (Amenta, 1990). Under 
electron microscopic examination needlelike hydroxyapatite crystals lie alongside the 
collagen fibers, both of which are surrounded by the somewhat amorphous ground 
substance. The association of hydroxyapatite with the collagen fibers is responsible for 
the strength and hardness characteristics of bone.
1.2 Bone Cells
Three primary cell types are involved in the formation and resorption of mature 
bone: osteoblasts, osteocytes, and osteoclasts. Based on morphological and histological 
studies, osteoblastic cells are categorized in a presumed linear sequence progressing from 
osteoprogenitor, preosteoblasts, osteoblasts, and then to transitory osteoblasts, secretory 
osteoblasts, osteocytic osteoblasts and finally to osteocytes (Nijweide et al., 1986; Martin 
et al., 1987; Marks et al., 1988). Morphologically, osteoblasts are defined as cuboidal, 
polar, basophilic cells which exhibit an abundant rough endoplasmic reticulum and Golgi 
complex and are responsible for the active matrix formation (Cameron, 1968; Holtrop, 
1975). In addition to morphological identification, specific products of cells are more 
frequently used in the characterization of phenotypes attributed to osteoblasts; these 
products include type I collagen (Leblond, 1989), osteocalcin (Hauschka et al., 1989), 
osteopontin (SPP1) (Bonucci, 1990), and bone sialoprotein (Sodek et al., 1992). High 
levels of alkaline phosphatase (ALP) activity is another biochemical marker of an 
osteoblast cell. Active osteoblasts give strong histochemical reactions for alkaline 
phosphatase which disappears when cells cease their synthetic activity and become
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embedded in matrix as osteocytes (Doty et al., 1976; Holtrop, 1975). Between the 
mineralized matrix and the main cell body there is a region of unmineralized matrix 
called osteoid which is secreted onto the surface of bone by osteoblasts. The main 
constituent of the osteoid is collagen in fibrous network form. Cell processes extend 
through this network deep into the osteoid. Membrane enclosed vesicles may be seen in 
the osteoid, but mineral crystals are not evident. Subsequently, bone mineral is deposited 
on the organic osteoid matrix. The osteoblasts eventually become surrounded by 
mineralized bone.
Once the osteoblasts become surrounded by a mineralized bone matrix, they 
progressively lose their bone forming capability. Their endoplasmic reticulum becomes 
less pronounced, the Golgi apparatus is reduced, and there are fewer mitochondria. When 
these changes become prominent, that is, when matrix production is no longer the 
primary role of the cell, it is termed an osteocyte. The osteocyte maintains an osteoid- 
containing space, or lacunae, between itself and the encroaching bone mineral. A special 
characteristic of osteocytes is their long processes which course through the Haversian 
canaliculi. These processes form junctions with other osteocytic and osteoblastic 
processes. These contacts and the canals they traverse provide a communication pathway 
linking all parts of a mineralized bone. Material fluxes to maintain localized cell and 
tissue viability move via these contact networks. The precise roles of the osteocyte 
population have not been determined.
Osteoclasts probably originate from monocytes unrelated to the progenitors of 
osteoblasts (Osdoby et al., 1982). This point has been debated extensively in the literature
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(Burmester, 1983; Horton et al., 1984; Osdoby et al, 1982; Zambonin Zallone et al., 
1983). However, it is clear that osteoclasts are specialized resorptive cells and are 
responsible for the resorption of bone. Morphologically, osteoclasts are large, 
multinucleated cells, each containing about 4 to 6 nuclei (Coccia, 1984). The surface of 
the osteoclast adjacent to the bone has a very ruffled appearance, which increases surface 
area and allows the cell to perform the task of bone resorption more effectively. During 
resorption osteoclasts secrete both acids and proteolytic enzymes into the extracellular 
space adjacent to the bone (Waite et al., 1969; Heath et al., 1984). The acidic 
environment increases the solubility of bone mineral, allowing the proteolytic enzymes to 
attack the organic matrix of the bone.
1.3 Endochondral Bone Formation
The development of bone follows two mechanisms: intramembranous ossification 
and endochondral ossification. During intramembranous ossification osteoblasts within a 
connective tissue begin producing the collagen fibers and matrix of bone. The area of 
ossification is very small at first. The bone enlarges as trabeculae extend into the 
surrounding tissue. The bony struts are forming an open framework that surrounds the 
blood vessels in the area. As the matrix enlarges osteoblasts become trapped within it. 
They then mature into osteocytes. This kind of bone formation initially resembles 
spongy bone, but the formation of additional matrix around the blood vessels can produce 
typical osteons. The roof skull, the lower jaw, and the collarbone are produced in this 
manner.
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Endochondral ossification of long bone begins with the formation of a 
cartilaginous model. By the time an embryo is 6 weeks old, the bones are composed 
entirely of cartilage. These models continue to grow by expansion of the cartilage matrix 
(interstitial growth) and the production of new cartilage at the outer surfaces (appositional 
growth). Ossification then begins, as diagrammed in Figure 1. As each cartilage enlarges, 
the chondrocytes near the center of the shaft become greatly enlarged, and the 
surrounding matrix begins to calcify (step 1). Deprived of nutrients, these chondrocytes 
die and disintegrate. Blood vessels invade the perichondrium surrounding the bone shaft, 
and the perichondrium converts to a periosteum (step 2). The cells of the inner, or 
osteogenic layer develop into osteoblasts, producing a superficial layer of bone around 
the shaft. Capillaries and osteoblasts then migrate into the heart of the cartilage, invading 
the spaces left by the disintegrating chondrocytes (step 3). The calcified cartilaginous 
matrix breaks down, to be replaced by the bone. Bone development proceeds from this 
center of ossification toward the ends of the cartilaginous model (step 4).
1.4 Bone Repair
Despite its mineral strength, bone cracks or even breaks if subjected to extreme 
loads, sudden impacts, or stresses from unusual directions. Repairs will usually occur 
even after severe damage, provided that the circulation supply and cellular components of 
the endosteum and periosteum survive. Stages in the repair process have been diagramed 
in Figure 2. In even a small fracture, many blood vessels are broken and extensive 
bleeding occurs. A large clot, or fracture hematoma, soon closes off the injured

















Figure 1. Endochondral bone formation. Step 1.Chondrocytes at the center of the cartilage model begin to disintegrate. Step 2. Blood 
vessels grow around the edges of the cartilage, and the perichondral cells convert to osteoblasts. The shaft of the cartilage then 
becomes ensheathed in a layer of bone. Step 3.The blood vessels penetrate the cartilage and invade the central region, growing toward 
the epiphyses at either end. The bone of the shaft becomes thicker and the cartilage near each epiphysis is replaced by shaft of 
bone.Step 4.Blood vessels invade the epiphyses and serve as a focus for secondary centers of ossification. Eventually the epiphyses 
will be coated in compact bone and dominated internally by spongy bone. The articular surface will remain cartilaginous and the thin 
epiphyseal plate will separate the spongy bone of the epiphysis from the marrow cavity o f the shaft.(Spencer et al, 1992)
7

















Figure 2. Fracture repair. Step 1. Immediately after the fracture, bleeding into the area creates a fracture hematoma. Step 2. An 
internal callus forms as a network of spongy bone unites the inner surfaces, and an external callus of cartilage and bone stabilizes the 
outer edges. Step 3. The cartilage of the external callus has been replaced by bone and struts of spongy bone now unite the broken 
ends. Fragments of dead bone and the areas of bone closest to the break have been removed and replaced. Over time the enlargement 
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vessels and leaves a fibrous meshwork in the damaged area. The disruption of circulation 
kills osteocytes around the fracture, increasing the size of the area affected and dead bone 
soon extends along the shaft in either direction from the break (step 1).
In the adult the cells of the periosteum and endosteum are relatively inactive. 
When a fracture occurs, the cells of the intact endosteum and periosteum undergo rapid 
mitoses, and the daughter cells migrate into the fracture zone. An enlarged collar or 
external callus forms, encircling the bone at the level of the fracture. An extensive 
internal callus organizes within the marrow cavity and between the broken ends of the 
shaft (step 2).
At the heart of each callus, the cells differentiate into chondrocytes and produce 
blocks of cartilage. At the edges of each callus the cells differentiate into osteoblasts and 
begin creating a bridge between the bone fragments on either side of the fracture. As the 
repair continues, osteoblasts replace the central cartilage with spongy bone. When this 
conversion is complete the external and internal callus form an extensive and continuous 
brace at the fracture site (step 3).
Osteoclasts and osteoblasts then remodel the region for a period ranging from 4 
months to well over a year. When the remodeling is complete, the fragments of dead bone 
and the trabecular bone of the calluses will be gone, and only living compact bone will 
remain. The repair may be as good as new, with no indications that a fracture ever 
occurred, but often the bone will be slightly thicker than normal at the fracture site.
Comparable events occur after complex bone breaks or even after transplantation 
of a bone fragment. Because dead bone is ultimately destroyed and replaced, dead and
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sterilized bone fragments from other individuals or even other species of animals can be 
used to establish a framework for the repair process.
Despite the considerable capacity for bone repair, every fracture does not heal as 
expected. A delayed union proceeds slower than anticipated. Nonunion may be the result 
of complicating infection, continued movement, or other factors preventing complete 
callus formation. Surgery and bone grafting are a major solution.
2. BONE INDUCTION
2.1 History of Bone Grafts
Bone grafts have been employed for more than a hundred years in orthopaedic 
surgery. They were used for discontinuity defects with loss of bone, such as traumatic 
congenital deformities; after resection for tumor; for contour, augmentation, or 
strengthening of bone, or as a scaffold.
Bone grafting has been a widely investigated area and autogenous bone is 
generally considered to be the most advantageous for grafting because it offers the 
advantages of a rapid healing response in osseous defects and ability to induce 
appreciable new bone formation (Burchard, 1983). However, autogenous materials have 
a number of disadvantage because the risks associated with a second surgery and the 
limited amount of graft tissue for large osseous defects. The alternatives to autogenous 
transplants are allografts.
More than a century ago, Senn reported the utility of antiseptic decalcified bone 
implants in the healing of osteomyelitis and other bone deformities (Senn, 1889). In
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1965, Urist, in the course of investigations on the biochemistry of recalcifying 
demineralized bone matrix, found that when implanted into muscle pouches in rodents, 
demineralized bone and dentin can induce chondrogenesis and then osteogenesis (Urist, 
1965). In the past 30 years, this bone regeneration with demineralized bone preparations 
has demonstrated potential in grafting procedures in surgical disciplines of both medicine 
and dentistry (Sonis et al, 1983; Mulliken et al, 1980; Mulliken et al, 1981; Pearson et 
al, 1981; Quintero et al, 1982; Mellonig et al, 1984; Glowacki et al, 1981). The 
osteoinductive potential of bone matrix is now well known, and the cellular and 
biochemical changes during bone induction have been well documented (Reddi et al,
1972,1981).
Although bone allografts have been used clinically for over one hundred years, 
they have undergone a tremendous increase in utilization over the last few years, with the 
finding that freezing and thawing o f grafts decrease antigenicity by about 90% and the 
dramatic development of organ procurement networks and tissue banks.
2.2 The Cellular Process of Bone Induction
After Urist's discovery, the cellular process associated with ectopic bone 
formation was studied and reported by Reddi (Reddi et al, 1972). They found that 
implantation of demineralized bone matrix resulted in an endochondral bone formation 
cascade, because of the chemotaxis, mitogenesis, and osteogenesis properties of 
demineralized bone matrix (Cunningham and Reddi., 1992). The cascade includes ten 
steps: 1) chemotaxis of progenitor cells, 2) mitosis of mesenchymal cells,
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3) differentiation of chondrocytes, 4) hypertrophy and calcification of cartilage matrix,
5) angiogenesis and vascular invasion, 6) differentiation of bone, 7) extracellular matrix 
biosynthesis and mineralization, 8) bone remodeling, 9) hematopoietic marrow 
differentiation, and 10) functional adaptation of bone.
In general, the induction of new bone formation can be described as the following: 
the implantation of DBM evokes a transient inflammatory phase (day 1), migration and 
proliferation of mesenchymal progenitor cells (day 2-4), differentiation to chondroblasts 
(day 5-7), and production of cartilage matrix that becomes calcified (day 11-12). After the 
cartilage becomes mineralized, it is invaded by vessels and chondrolysis begins. 
Eventually, the cartilaginous tissue is replaced by bone (Reddi et al., 1972). This 
endochondral sequence is similar to the process that occurs in embryonic skeletogenesis 
in the elongation of long bones, and in the healing of fractures. Even when implanted in 
membranous bone sites, demineralized bone matrix induces the endochondral sequences 
(Mulliken et al., 1980).
2.3 Species Limitation of Bone Induction
The osteoinductivity of demineralized bone matrix appears to be somewhat 
species specific. Sampath and Reddi demonstrated that in rats, subcutaneous implantation 
of allogeneic bone can induce bone formation, whereas xenogeneic implantation of 
human, monkey or bovine demineralized bone matrix evoked inflammatory reactions 
with little or no new bone production (Sampath and Reddi, 1983). Further study was done 
by extracting bone matrix from several species with 4 M guanidine hydrochloride. The
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total extract and partially fractionated extracts were then reconstituted with inactive, 
insoluble collagenous matrix and implanted in rat again to assess the osteoinductivity.
The results showed that although the intact bone matrix and the total extracts of each 
species exhibited very low osteoinductivity, the dissociatively extracted and partially 
fractionated matrix components of less than 50 Kda induced significant amounts of bone 
formation. The results implied that the bone morphogenetic proteins from diverse 
mammalian species are homologous. The species specificity of bone induction is most 
likely due to soluble inmmunogeneic or inhibitory components of greater than 50 Kda 
within the non-morphogenetic, non-collagenous matrix proteins.
This hypothesis was tested by Aspenberg (Aspenberg et al., 1988) using athymic 
rats. The immune system consists of T-lymphocytes which are responsible for cell- 
mediated immunity, and B-lymphocytes which are responsible for the humoral immune 
system. Athymic rats are deficient in the thymus gland and therefore lack mature T- 
lymphocytes necessary to initiate an immunologic rejection of foreign materials. In 
Aspenberg's study, implantation of xenogeneic DBM into athymic rats induced a 
significant amount of bone formation comparable to implantation of allogeneic DBM in 
normal immunocompetent rats. This study proved that the species specificity is due to 
immunogenic rejection, and substantiates the use of the athymic rat as a xenogeneic 
model for the bioassay of osteoinductivity of human or other species DBM.
2.4 The Discovery of Bone Morphogenetic Protein
The search for bone inductive factors present in bone matrix led to the discovery
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of bone morphogenetic proteins (BMPs). BMP hypothesis suggested that BMP is 
released from a supra molecular aggregate of noncollagenous proteins in the process of 
normal bone turnover or in response to injury or transplantation. BMPs are part of 
insoluble noncollagenous proteins closely associated with bone collagen (Urist et al., 
1983b). BMPs can be extracted from bone matrix with 4M guanidine hydrochloride, 6 M 
urea in 0.5 M calcium chloride (Urist et al., 1979a), or ethylene glycol in a mixed 
aqueous-nonaqueous solvent (Urist et al., 1979b). The quantity of human BMPs in bone 
is less than 1 pg/kg (Urist et al., 1983b). Therefore considerable quantities of bone matrix 
are needed to extract small amounts of BMPs. Eight molecular species, BMP 1-8 have 
been found to date. Seven of them, BMP-1 through BMP-7, have been purified, 
identified and cloned using fragmentary amino acid sequence information (Wozney,
1988,1989; Celeste et al., 1990).
From the primary amino acid sequences of the human BMPs derived from these 
molecular clones, six out of the seven BMPs are found to be related to each other and to 
be members of the transforming growth factor-beta (TGF-beta) superfamily. Analysis of 
amino acid sequences (Figure 3) indicated that significant amino acid identity exists in 
the carboxyl terminal region of all the BMPs. This region contains seven cysteine 
residues which are a highly conserved motif that is characteristic of the TGF-beta 
superfamily. Like all members of TGF-beta, BMPs are synthesized in a precursor form 
(Figure 4) with hydrophobic secretory leader sequences, followed by a long, poorly 
conserved N-terminal propeptide region, and a short, highly conserved mature portion 
which includes the seven cysteine domains at the carboxyl-terminus of the prepropeptide.

















Figure 3. Alignment of the amino acid sequences of the bone morphogenetic proteins (BMPs). Asterisks indicate positions where an 
amino acid residue is conserved among all six proteins. Residues that are conserved among BMP-2/BMP-4/BMP-5/BMP-6/BMP-7 
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Figure 4. Schematic structure of the bone morphogenetic proteins (BMPs). Nomenclature and biochemical characteristics of the BMPs 





































BMP-2 BMP-2A 396 114 1
BMP-4 BMP-2B 408 116 2
BMP-5 454 138 3
BMP-6 Vgr-t 513 139 3
BMP-7 OP-1 431 139 3
BMP-3 Osteogenin 472 ? 1
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The mature forms of BMPs are disulfide-linked homodimers.
Most of the human BMP genes have been assigned to specific chromosomes 
(Dickinson, 1990; Cecil, 1990). BMP-1 gene is localized to chromosome 8, where it is a 
candidate gene for the multiple hereditary osteochondromatosis. BMP-2 and BMP-7 are 
both localized on chromosome 20, and may be the Holt-Oram syndrome locus. BMP-3 
and BMP-4 are localized to chromosome 4 and 14, respectively, and BMP-5 and BMP-6 
are both localized on chromosome 6.
2.5 Osteoblast Phenotypic Expression and Osteoblast Markers
Several characteristics have been proven useful in the identification of cells within 
the osteoblast lineage. Of these, high alkaline phosphatase activity, parathyroid hormone 
(PTH) binding and a PTH-stimulated adenylate cyclase reaction, and the ability to 
synthesize a number of noncollagenous bone matrix proteins are important features.
2.5.1 Alkaline phosphatase Activity
Alkaline phosphatase (ALP EC 3.1.3.1) is an ectoenzyme that can optimally 
hydrolyze monophosphate esters at an alkaline pH (Wuthier et al., 1984; Harris, 1989; 
White, 1989). Three different genes encode for different tissue-specific isoenzymes: 1) 
the placental, 2) the intestinal, and 3) a so called bone-liver-kidney isoform. ALP is 
anchored onto cells by being covalently bound to phosphatidyl-inositol (PI) phospholipid 
complexes in the plasma membrane (Corss, 1987; Ferguson et al., 1988; Low, 1989), and 
belong to a growing class of cell surface proteins, including Thy-1 and N-CAM.
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Membrane-bound ALP can be released from cells (e.g., the ROS and UMR cell lines) by - 
Pi-specific phospholipase C ( Noda et al., 1987; Turksen et al., 1991).
Alkaline phosphatase is localized predominantly in preosteoblasts and osteoblasts, 
particularly in growing bone and cartilage (Teaford et al., 1964; Timmer et al., 1968).
ALP is absent from the osteocytes, while one or more acid phosphatases are found in 
osteoclasts (Doty et al., 1976). To date the mode of action and function of bone alkaline 
phosphatase are not known. Activity is greater in the newly calcified areas of fractures 
and in the epiphyseal plate of man and animals than in resting bone (Granda et al., 1971).
It is generally accepted that as the specific activity of ALP in a population of bone cells 
increases there is a corresponding shift to a more differentiated state, and the level of 
osteoblastic ALP has been routinely used in in vitro experiments as a relative marker of 
osteoblast differentiation (Rodan et al., 1984).
In histology observations, ALP is found present on preosteoblastic cells prior to 
assuming the cuboidal shape typically associated with the mature osteoblast. Recent 
studies also suggest that ALP expression appears in differentiating osteoblastic cells prior 
to expression of the matrix molecule osteocalcin (Broachers et al., 1987; Aronow et al., 
1990; Owen et al., 1990). Although the function of ALP is commonly associated with 
mineralization, the precise role of ALP is still under investigation (Heersche et al., 1990). 
Recently, it is has been suggested that Pi-linked proteins may be involved in 
transmembrane signaling (Saltier et al., 1989; Low, 1989). Therefore, it is possible that 
instead of playing a role in mineralization ALP may play a role in the regulation of 
osteoblast differentiation.
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2.5.2 Hormone and Growth Factor Response
The response of osteoblastic cells to parathyroid hormone (PTH) is through 
adenylate cyclase (Peck et al., 1988). The distribution of PTH receptors in the osteoblast 
cell line are still not quite clear. Earlier, PTH receptors were considered a characteristic 
of osteoblasts because they were demonstrated on osteoblasts and their immediate 
precursors (Silve et al., 1982; Rao et al., 1983). However, some recent studies suggest 
that the highest number of receptors is on a variety of undifferentiated cells, with 
relatively few on the mature osteoblast itself (Rouleau et al., 1990).
Expression of many of the osteoblast phenotypes is influenced by prostaglandins 
(PGs) (Harvey, 1988). Different osteoblast populations have been shown to synthesize 
and /or respond to PGE2 (Aubin et al., 1982). It has been suggested that the ability to 
respond to PGE2 is a marker of a less differentiated osteoblastic cell, but confirmation of 
such a hypothesis awaits further proof.
A variety of growth factors have effects on osteoblastic cells. These growth 
factors include: insulin-like growth factors I and II, epidermal growth factor (EGF), 
fibroblast growth factor, platelet-derived growth factor, and transforming growth factor- 
beta (TGF-beta); other molecules with potent activities are cytokines such as interleukin- 
1 (Canalis et al., 1989). The effects of these agents on osteoblastic cells are heterogenous 
(stimulatory, inhibitory, no effect) according to different people in different model 
systems (Nijweide et al., 1988; Heersche et al., 1990). It is also suggested that the ability 
of these agents to regulate osteoblast properties and differentiation is complex and may 
be dependent on timing, concentration, and whether other agents are present. It is
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relatively difficult to discriminate stages of the osteoblastic lineage based on the effects 
of these hormones on cell function.
2.5.3 Bone Matrix Proteins
The most abundant protein in bone is type I collagen, which constitutes 95% of 
the organic composition. However the noncollagenous proteins are being rigorously 
studied (Boskey, 1989; Low, 1989). The most interesting noncollagenous proteins are 
osteocalcin, osteonectin, and sialoproteins.
Osteocalcin is found only in bone, teeth, and mineralizing cartilage. Its 
distinguishing feature is the presence o f three residues of gama-carboxyglutamic acid per 
molecule added via posttranscriptional modifications in a vitamin K-dependent process 
(Price, 1988; Hauschka et al., 1989). The exact role of osteocalcin is not known. 
Osteonectin is not exclusively an osteoblast product. It can be synthesized by fibroblasts 
of various sites (Wasi et al., 1984; Tung et al., 1985,1986), and by parietal endoderm 
(Sage et al., 1989). There are two types of sialoproteins in bone, osteopontin and bone 
sialoprotein. Osteopontin (also termed bone phosphoprotein, bone sialoprotein I, secreted 
phosphoprotein I, SPP) ( Price., 1988) is an Arg-Gly-Asp-Ser (RGDS) containing, 
phosphorylated, sialic acid-rich, Ca-binding protein (Senger et al., 1989). Osteopontin is 
present in the bone matrix, osteoblasts, osteocytes, and stroma cells in bone marrow. Like 
osteonectin, osteopontin is not a bone exclusive protein. Other cells, like the proximal 
convoluted tubules of kidney, chondrocytes, neurons, and sensory and secretory cells in 
the internal ear express osteopontin (Mark et al., 1988). Osteopontin is thought to be an
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
24
earlier marker than osteonectin for identification of osteoblast precursor cells. Bone 
sialoprotein (BSP) is another type of sialoprotein found in bone. BSP has a high content 
of sialic acid and glutamic acid and is more highly sulfated than osteopontin (Ecarot et 
al., 1989). BSP is present in the mineralized matrix of bone but also is present in the 
mineralized zone of hypertrophic cartilage (Senger et al., 1989). BSP mRNA is restricted 
to sites of newly mineralized tissue (bone and calcifying cartilage) with less expression in 
older bone (Chen et al., 1991).
3. PURPOSE OF THIS STUDY
3.1 The Establishment of in vivo and in vitro Assay Models
Due to the ability of DBM to induce new bone formation, bone has became one 
of the most frequently transplanted tissues in humans, and is routinely used for the repair 
of skeletal defects caused by trauma, neoplasia, infection, and periodontal disease.
Several investigators have studied the use of demineralized bone matrix, or similar 
materials, as bone grafts in human (Borghetti et al., 1993; Bowers et al., 1991; Bolander 
et al., 1986; Glowacki et al., 1981a). Reports from these clinical studies are promising. 
Since demineralized bone matrix is easy to prepare and can be stored for extended 
periods, it is an ideal material for bone-grafting.
One unsolved problem in the application of demineralized bone grafts is the need 
for a quantitative means of assessing the osteoinductivity of bone matrix from different 
donors. It is believed that the osteoinductivity of DBM is primarily due to BMPs 
contained in the matrix (Sampath et al., 1981; Urist et al., 1982,1983), although the
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osteoconductive role of the matrix itself should not be ignored. The osteoinductivity of 
DBM is not an " all or none" effect, but depends upon the quality and quantity of BMPs 
in the bone matrix (Vukicevic et al., 1989; Sampath et al., 1992), and previous studies 
have shown that there is a dose-response curve with BMPs (Sampath et al., 1992). Thus 
the osteoinductive ability of DBM is an important product quality factor which should be 
considered before clinical application. This study is directed at establishing a quantitative 
means of assessing osteoinductivity of DBM by use of in vivo and in vitro assays.
3.2 The Effect of Demineralized Bone Matrix Processing
Osteoinduction associated with implantation of demineralized bone matrix 
(DBM) is mainly due to the presence of a collagen matrix and protein factors such as the 
BMPs (Urist et al., 1981,1982,1983a). These BMPs can be extracted from DBM with 
guanidine hydrochloride (Anastassiades et al., 1978; Takaoka et al., 1980), resulting in 
the development of several recombinant BMPs. After separation, neither the extracted 
proteins (BMPs) nor the residue (extracted bone matrix) is capable of inducing bone 
formation. However, they can be recombined to produce a bioactive bone-inducing 
matrix (Sampath et al., 1983). In addition, the localization of fibronectin on the surface of 
the DBM particles has been demonstrated to be necessary for DBM-induced ossification 
(Weiss etal., 1981).
Previous studies have demonstrated that physical characteristics, such as, particle 
size and calcium phosphate (hydroxyapatite) composition may somewhat affect 
osteoinductivity (Urist et al, 1970). Currently, the residual calcium content in human
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demineralized bone matrix products is defined as less than 5% by American Association 
of Tissue Bank Standards and the particle size range most commonly used is 250 microns 
to 710 microns. The exact effects these factors have on osteoinduction have not been 
elucidated. This present study is directed at investigating the effect(s) of residual calcium
jc^m tentundJhe^efibcl^of^articfe-size^caxne^boneJbrm atiorU ndiicedhyJium an-----------
derived DBM. The present study addressed the hypothesis that, within certain limits, the 
demineralization process and bone particle size affect the osteoinductivity of DMB. The 
importance of these observations to processing of demineralized bone matrix is discussed.
3.3 The Effect of Donor Age and Gender
Bone mass is affected significantly by age. As shown in Figure 5, following the 
growth of skeletal tissue, there is a period of consolidation over about fifteen years, with 
further calcium accretion, decreased cortical porosity and increasing cortical thickening. 
Peak adult bone mass is attained at about middle age, from 30 to 50, then declines with 
aging. Bone mass is also different among gender and races, with individuals of the Black 
race (both male and female) demonstrating a higher bone mass than individuals of the 
Caucasian race. Males usually have higher bone mass than females. The age distribution 
of fractures is bimodal (Figure 6) with a peak fracture incidence in youths around age 5- 
14 years old which declines to a low point for females between ages 15-44 and males 
between ages 25-64. The incidence of fracture formation starts to increase for females 
from age 50 and up and for males from age 65 and up (Garraway et al., 1979).
It is reasonable to assume that donor age may have a big effect on the quality of

















Figure 5. Schematic representation of effects of age, sex, and race on bone mass. Note the Black females ( ) and males ( ) have 
greater bone mass complements than either white females ( ) or white males ( ), and that the white females have the lowest bone mass 
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demineralized bone matrix. As we can see from the above, bone mass and strength are 
affected largely by age and gender. However, the effects of age and gender on the 
osteoinductivity of derived bone grafts have not been elucidated. It is therefore 
appropriate that this study focuses on the effect(s) of age and gender on the 
osteoinductivity o f derived DBM and will provide a scientific basis for determining the 
quality of allograft bone products in the early stages of bone procurement and processing.
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1. ESTABLISHMENT AND HUSBANDRY OF ATHYMIC MOUSE POPULATION
Breeding pairs of athymic mice, male (nu/nu) and female (nu/+), were purchased 
from Harlan (Harlan Sprague Dawley, Inc., Indianapolis, Indiana). Each male (nu/nu) 
was put together with 3 or 4 females (nu/+) in breeding cages with a floor area of 68.1 
square inches for mating.
Prior to 6 weeks of age female and male litters were pooled and placed in separate 
cages with a floor area of 126 square inches, and maintained using standard protocol.
All athymic mice, breeding pairs and mice used in experimental procedures, were 
maintained in cages with sealed air filter covers. Sterile fine hardwood bedding chips 
were used for breeding mice and litters. All cages, filters, bedding, food, and water 
bottles were autoclaved before use. Temperatures in the athymic mouse room were 
maintained at 26-28 °C and humidity at 40-60%. Ventilation was maintained by high 
efficiency particulate air filtration (HEPA) with 10-15 air changes per hour. A 10 hour 
light-14 hour dark cycle was controlled by automatic timer.
2. DBM
Sterile human DBM, size 250-750 micron, was generously provided by LifeNet
Transplant Services, Virginia Beach, Virginia.
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3. ASEPTIC TECHNIQUE
The instruments, size 3 scalpel handle and No. 10 blade, pointed dressing scissors, 
small scissors with tapered tips, DeBakey forceps, Michael wound clips and applicator, 
gauze swabs and cotton tipped applicators were packaged in autoclave pouches (DualPeel 
Pouche) and sterilized by steam autoclave under pressure of 15 lb/in2 for 20-30 minutes.
Surgical procedures were conducted under horizontal flow of HEP A filtered air on 
a table surface which was cleaned with disinfectant and covered with a sterilize drape.
4. ANAESTHESIA
Athymic mice used for surgery, usually 10-20 weeks old, were tranquilized with 
acepromazine (1.1 mg/kg, PromAce, Ayerst Laboratories, Inc., New York)). Two minutes 
later the animals were anaesthetized with sodium pentobarbital (0.44 ml/kg, Somnifer, 
Richmond Veterinary Supply Company, Richmond, Virginia). The administration of both 
tranquilizer and anaesthesia were through intraperitoneal injection with a sterile lcc 
syringe (plastic disposable, Luer-Lok tip) attached to a size 27 G 1/2 inch hypodermic 
YALE needle (Becton, Dickson and Company, Rutherford, New Jersey).
5. CHECKING OF THE DEPTH OF ANAESTHESIA
The depth of anaesthesia was monitored by the presence or absence o f the pedal 
withdrawal reflex response. The animal's hind limb is extended and the skin between the 
digits is pinched firmly with fingernails. If the animal attempts to withdraw its limb, then 
it is not sufficiently anaesthetized to allow major surgery to be undertaken. If there is no
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response, medium or deep surgical anaesthesia has been achieved and the animal is ready 
for surgery.
6. PREVENTION OF HYPOTHERMIA
Athymic mice in the condition of medium anaesthesia were kept on a heat pad 
with temperature of about 28 °C. The heat pad can be a commercially available heating 
pad or a flat bottle containing water at the desired temperature. Sterilized paper sheets 
should be placed between the animal and heating pad.
7. IMPLANTATION
The area of the incision site was swabbed from the middle outward with 70% 
isopropyl alcohol and the area dried immediately with sterilize gauze. A 1 cm long 
incision was made along the dorsal midline through the skin and subcutaneous tissue near 
the gluteal region. The incision was made using a No. 10 blade (sterile, stainless steel, 
American Scientific Products, Illinois) on a scalpel handle size 3. Blunt dissection was 
made between the skin and the tissue below with small tapered scissors. The fascia of the 
longissimus dorsi muscle was pulled up with forceps and cut over the implantation sites 
with small pointed dressing scissors. A muscle pouch was created between fascia and the 
gluteus maximus by blunt dissection. DBM rehydrated with saline (30 minutes before 
the surgery) was packed into the muscle pouch. The muscle pouch was closed with 
continuous sutures of 6-0 polypropylene. The skin was closed with discontinuous sutures 
of 6-0 polypropylene and 9 mm Michael wound clips applied on top of the sutures.
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8. Explantation
At prescribed time intervals, animals were sacrificed by cervical dislocation. The 
DBM implants were dissected from the implantation sites and referred to as “explant” at 
this time. Excess tissue (mainly muscle tissue) was carefully cleaned from explants.
9. Animal Treatment
In conducting the research on athymic mice, the investigators adhered to the 
“Guide for the Care and Use of Laboratory Animals” (NIH publication 85-23) as 
promulgated by the committee on Care and Use of Laboratory Animals of the Institutes 
of Laboratory Science, the National Academy of Sciences, and the National Research 
Council.
10. HISTOLOGICAL EVALUATION
One half of the explant from each implantation site was fixed in 10% neutral 
phosphate buffered formalin for at least 24 hours, decalcified for 48 hours in 10% formic 
acid solution, embedded in paraffin, sectioned, and stained with hematoxylin and eosin 
prior to examination by light microscopy.
11. CALCIUM DETERMINATIONS
Explants for chemical evaluation were dried at 95 °C for 48 hours, weighed to the 
nearest 0.1 mg with an analytic balance, ashed at 600 °C overnight, dissolved in 1 N HC1 
and the content of calcium determined by the Arsenazo III assay kit (Sigma) with
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modification as described by Homsi and Wolfinbarger (1994). Basically, 100 jj.1 samples 
are mixed with 4.0 ml of 0.05% Arsenazo III solution (0.5 M Tris buffer, pH 7.4) and 
absorption measured at 650 nm. Linearity exists over the calcium concentration range of 
0.1 pg/ml to 1 pg/ml (R2 = 0.9991, Figure 7). Calcium concentrations were calculated 
from a standard curve over a concentration range from 0.1 pg/ml to 1 pg/ml. The calcium 
content was expressed as weight percent calcium of explant dry weight.
Based on previous work of this laboratory (Homsi et al., 1994), the linearity of 
calcium assay was validated. The Arsenazo III assay protocol used in this study provided 
a standard curve with a coefficient of determination (R2) of 0.9991. Linearity exists 
between the concentration range of 0.1 pg/ml to 1 pg/ml, and all of the assays in this 
study were carried out between this range. A standard curve was prepared at the time of 
each assay.
12. INITIATION OF PERIOSTEAL CELL CULTURES
Periosteum from an adult male (26 years old) femur was obtained during routine 
tissue procurement by LifeNet staff with consent of next of kin. The periosteum was 
washed 3 times with Minimum Essential Medium Eagle (MEM, Sigma Chem. Co., 
M4526) containing 200 units/ml penicillin and 100 pg/ml streptomycin, cut into 0.3 mm 
X 0.3 mm pieces, and placed with the internal stratum osteogenicum layer facing toward 
the surface of the T-25 flasks. The preparation was cultured in alpha-MEM supplemented
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with 10% fetal bovine serum (FBS) and penicillin (100 units/ml) /streptomycin (50 
pg/ml) in a 5% C 02 incubator at 37 °C. The outgrowing cells were combined and 
transferred into T-75 flasks by detachment with a 0.025 % trypsin and 0.05% EDTA 
solution and cultured in the same media and incubator. When cells reached confluence,
they were split into new T-75 flasks at split ratios of 1:4.___________________________
13. CRYOPRESERVATION OF HPO/CB-MZ01 CELLS
Passages 3-5 periosteal cells were cryopreserved to establish a cell bank. Cells 
were treated with typsin (0.025% trypsin in 0.05% EDTA solution), neutralized with 
MEM supplemented with 10% FBS and sedimented by centrifugation at 1,000 rpm for 5 
minutes. Cell pellets were resuspended in freezing solution (20% FBS and 10% DMSO in 
MEM) at a concentration of 2 x 106 cells/ml and 1 ml aliquots were placed into sterile 
ampules. Ampules plus cells in a styrofoam box were placed in refrigerator (+4 °C) for 1 
hour, transferred into a freezer (-20 °C) for 1 hour, a -70 °C freezer for overnight, and 
lastly transferred to -140 °C for long term storage.
14. CELL THAWING AND CULTURE
For experimental use, ampules of frozen cells were quickly removed from the 
-140 °C storage freezer, thawed in a 37 °C water bath for 2 minutes and the cells 
immediately transferred into T-75 flasks with 20 ml of MEM supplemented with 10% 
FBS, and put into a 37 °C, 5% C 02 incubator. When cell cultures reached confluence, 
HPO/CB-MZ01 cells were treated with trypsin and split 1:4 into new T-75 flasks until
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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15. CULTURE OF CELLS USED IN THE IN VITRO BIOASSAY
When appropriate numbers of HPO/CB-MZOl cells were obtained, cells were 
treated with trypsin, neutralized with 10% FBS, and sedimented by centrifugation at 
1,000 rpm for 5 minutes. Cell pellets were resuspended in small volumes of MEM 
supplemented with 10% FBS and pooled into one T-75 flask. Pooled cell suspensions 
were mixed well by trituration and counted using a hemacytometer. Cells were seeded 
into T-25 flasks at 6.25 X 105 cells per flask (or 2.5 x 104 cells/cm2). These cell cultures 
were maintained in 10 ml of alpha-MEM supplemented with 10% fetal bovine serum 
(FBS) and penicillin (100 units/ml) /streptomycin (50 pg/ml) until reaching confluence. 
The alpha-MEM medium was then changed to 10 ml of Dulbecco's Modified Eagles' 
Medium (DMEM) (Sigma, D8788) supplemented with 2% FBS. Five mg of rehydrated 
DBM or non-DBM (as a control) were added into appropriate flasks immediately 
following changing of the medium to DMEM. During in vitro assays the flasks for 
experimental and control wrere randomly assigned at the time of addition of DBM.
16. ALKALINE PHOSPHATASE STAINING IN THE IN  VITRO BIOASSAY
Cell layers were rinsed with 0.9% NaCl, fixed in citrate-acetone-formaldehyde 
fixative at room temperature for 30 seconds and stained for endogenous alkaline 
phosphatase activity with FVR-Hematoxylin for 10 minutes using a commercially 
available kit (Sigma).
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17. ALKALINE PHOSPHATASE ASSAY IN THE IN  VITRO MODEL
Alkaline phosphatase (ALP) activity was measured by the method developed by 
this laboratory (Wolfinbarger and Zheng, 1993). Generally, treated cells were quickly 
washed twice with 3 ml deionized water, scraped with a cell scraper (Fisherbrand) in 3 ml 
deionized water and sonicated at 30% intensity (Virsonic Cell Disrupter model 16-850) 
for 30 seconds. Sonicated cells were extracted with equal volumes of n-butanol and 
centrifuged at 2000 rpm for 10 minutes. The aqueous layer (bottom layer) was transferred 
into a clean glass tube with a Pasteur transfer pipet. One ml aliquots of samples were 
mixed with 0.2 ml 100 mM p-nitrophenyl phosphate (PNPP) in 0.15 M 2-amino-2- 
methyl-1-propanol buffer, pH 10.4, and incubated in a 37 °C water bath for 15 minutes. 
The reaction was stopped by addition of 50 pi 1 N NaOH and absorbance at 405 nm was 
measured. The production of p-nitrophenol (PNP) was calculated from a standard curve, 
p-nitrophenol concentrations range from 0.1 to 1 pmole/ml was used in establishing a 
standard curve. Protein concentrations of the samples were assayed by using the BCA 
(Pierce, Rockford, IL ) protein assay. The ALP activities were expressed as units of 
enzyme (EU) ( 1 EU = pinole p-nitrophenol/min/mg cell protein).
Linearity of the standard curve used in the ALP assay was studied and 
representative curves are shown in Figure 8 and Figure 9. Between p-nitrophenol 
concentrations of 0.1 to 1.00 pmole, the absorbance at 405 nm as a function of p- 
nitrophenol concentration can be expressed as 175.97X + 2.9, where X represents the 
concentration of p-nitrophenol (range from 0.1 to 1.0 pmole) (R2 = 0.9975). Between 1 
and 10 pmoles p-nitrophenol, the absorbance as a function of the concentration of

















Figure 8. PNP Standard curve for ALP assay.!. Authentic p-nitrophenol was prepared in 0.15 M 2-amino-2-methyl-l-propanol buffer 
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Figure 9. PNP Standard curve for ALP assay .II. Authentic p-nitrophenol was prepared in 0.15 M 2-amino-2-methyl-l-propanol buffer 
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p-nitrophenol can be expressed as 183.17X + 19.417, where X is the concentration of p- 
nitrophnol (range from 1 to 10 pmole) (R2 = 0.9999).
The kinetics of the ALP were studied and shown in Figures 10 and 11. In this 
study, the ALP was extracted with n-butanol as described in the ALP assay protocol and 
used in the ALP kinetics study. The reaction rates (PNP produced, pmole/min/mg 
protein) were plotted against their respective substrate concentration and the acquired 
curve (Michaelis-Menten plot) is shown in Figure 10. The specific Km and Vmax values 
were derived from the double reciprocal plot as shown in Figure 11. Vmax was 5.6 pmole 
PNP produced per min per mg protein. The Km was 1.2 mM. The current ALP assay 
protocol is set at providing a final substrate concentration of 10 mM p-nitrophenyl 
phosphate ( or 100 mM, in 0.15 M 2-amino-2-methyl-l-propanol buffer, pH 10.4, as 
stock solution), which is sufficient to saturate the ALP extracted from the HPO/CB- 
MZ01 cells and allow it to proceed at a maximum rate for the prescribed time interval 
used in the assay.
Stability of ALP activities was investigated to ensure a precise and accurate assay 
irrespective of the assay times required in given experimental procedures. ALP samples 
from cells incubated with DBM for 5 days were collected. The ALP activities were 
assayed at the time of collection with the remaining ALP samples stored in a refrigerator 
(4 °C) and a freezer (-20 °C), respectively. The ALP activities were then assayed on day 3 
and day 6 of storage. The results are shown in Figure 12. When stored at 4 °C, ALP 
activity declined from 11.2 units to 6.6 units after 3 days storage, i.e. 56% of its original 
activity. After 6 days storage ALP activity dropped to 3.76 units, i.e. 33.6% of its original
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Figure 12. The stability of ALP. The ALP samples were extracted from HPO/CB-MZOl cells and stored at 4 °C and -20 °C. The ALP 
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activity. This decline in ALP activity corresponded to an approximate 11% decline in 
ALP activity for each day of storage at 4°C during the 6 days total. When stored at -20 
°C, the ALP activity dropped more slowly than ALP stored in a refrigerator. At day 3 the 
ALP activity was 10.5 units, i.e. 93% of its original activity, and at day 6 the ALP 
activity was 10.1 units, i.e. about 89% of its original activity. Over the 6 days of storage 
in a freezer, the activity of ALP declined at about 1.8% each day. Based on these studies, 
all cell derived ALP samples were assayed immediately after scraping cells. In case 
samples must be assayed the next day, samples were stored in a -20 °C freezer and 
assayed as soon as possible, but never longer than 3 days.
18. ALKALINE PHOSPHATASE ASSAY IN THE IN  VIVO MODEL
At the time of ALP activity assays in the in vivo model, the implants were 
dissected out, cleaned of attached tissue, and homogenized in 5 ml 0.15 M 2-amino-2- 
methyl-1-propanol buffer (pH 10.4) using tissue grinders (Fisher Scientific, Pittsburgh, 
PA). The homogenate was centrifuged at 3000 rpm for 10 minutes. The supemate was 
extracted with n-butanol and the ALP activity was measured by the method described in 
section 17.
19. PREPARATION OF BONE MATRIX WITH DIFFERENT WEIGHT 
PERCENTAGES OF RESIDUAL CALCIUM
Ground bone matrix (particle size range 250 to 710 microns) obtained from
LifeNet Transplant Services was demineralized in 0.5 N HC1 (200 mg DBM to 20 ml 0.5
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N HC1). Variably demineralized bone matrices were obtained by removing bone matrix 
from the acid at 45 minute intervals, i.e., 45,90,135,180 minutes, and then allowing a 
prolonged demineralization process (300 minutes). The variably demineralized bone 
matrices were washed, freeze dried and stored at -80 °C. The demineralization process 
was performed aseptically with no additional sterilization of the DBM prior to use in 
bioassays.
20. PREPARATION OF DIFFERENT PARTICLE SIZES OF HUMAN DMB
Freeze dried human cortical and cancellous bone was ground by impact 
fragmentation and separated using a series of variably sized sieves. Samples were 
collected according to the following particle size ranges: <250 micron, 250-355 micron, 
355-500 micron, 500-710 micron, and 710-850 micron. Samples were then 
demineralized in 0.5 N HC1 (200 mg DBM to 20 ml 0.5 N HC1) and the demineralization 
process was stopped when the pH value of the solution dropped below 1. Residual 
calcium levels were measured using a modification of the Arsenazo III Calcium Assay 
(Sigma Chemical Company).
21. STATISTICAL ANALYSIS
Each data point consists of at least 3 replicates in all assays. Prior to statistical 
evaluation the data were tested for normal distribution. Linear regression analyses were 
used to derive standard curves and analysis of variance (ANOVA) was used to determine 
the significance among treatment groups. Fisher's multiple tests were used for comparing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
means of more than two groups in one way ANOVA analyses. Scheffe multiple tests 
were used in two way ANOVA analyses. Significance level was assigned at P < 0.05.
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I. VALIDATION OF IN  VIVO AND IN VITRO BIOASSAYS 
1. VALIDATION OF THE IN  VIVO ANIMAL BIOASSAY MODEL
1.1 Sites Of Implantation
Two implantation sites were described in previous studies (Urist, 1965; Reddi et 
al., 1972,1976; Glowacki et al., 1981a; Guterman et al., 1988; Bemick et al., 1989) of 
bone induction in extra skeletal sites. One site involved subcutaneous implantation 
(Reddi et al., 1976; Bemick et al., 1989) and the other was intramuscular implantation 
(Urist,1965; Glowacki et al., 1981; Guterman, 1988). Subcutaneous implantation is a site 
just beneath the skin (between skin and fascia). In this study, with the intramuscular 
pouch, the site can be divided into two kinds of pouch. In one situation, the muscle was 
bluntly dissected and the pouch was created within the gluteus maximus muscle tissue 
(Figure 13), this method is referred to as an "intramuscular pouch". In the other case the 
muscle pouch was created between the layers of muscle. In this situation the muscle was 
not damaged when creating the pouch, this method is referred to as a "muscle pouch". In 
this study, the muscle pouch was specifically between the subcutaneous maximus and 
fascia (Figure 13), and was created along the sides of the spine near the gluteal area.
1.2 Effects of Implantation Sites on Osteoinduction
Quantitative assessment of osteoinductivity requires a consistent condition so
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the osteoinductivity can be compared. The effect of implantation sites on 
osteoinductivity were studied to see if  different implantation sites affect osteoinductivity 
and which is the best. In order to assess the effect of implantation sites on the 
osteoinductivity of DBM, equivalent amounts of specific lots of DBM (20 mg) were 
implanted into subcutaneous, muscle and intramusclar pouches. Remineralization of 
explants from each site were assayed at week 4 post implantation, expressed as percent 
calcium of explant dry weight and compared as shown in Figure 14. The calcium content 
of DBM before implantation was 0.5 +/- 0.048 percentage of the dry weight of DBM . 
After four weeks of implantation, explants from subcutaneous pouches exhibited slight 
remineralization (1.62 +/- 0.27 percent calcium of explant dry weight) which was not 
considered sensitive enough for a good assay of osteoinductivity. Explants from 
intramuscular pouches gave the highest degree of remineralization (12.4 +/- 0.27 percent 
calcium of explant dry weight), but creation of this site causes bleeding and extensive 
tissue trauma. Explants from muscle pouches yielded 10.0 +/- 0.4 percent calcium of 
explant dry weight, which is 20 times the calcium content of the DBM before 
implantation, and provides a good indicator of mineralization in the in vivo model. The 
advantage of the muscle pouch is that it has no bleeding, minimal tissue trauma, and yet 
exhibits a high level of remineralization of explant at week 4.
1.3 Histological Evaluation
The time dependent process of new bone formation in response to the

















Figure 14. The effects of different implant sites on osteoinductivity of DBM. Subcutaneous pouches, muscle pouches and 
intramuscular pouches were created in the same athymic mice and 20 mg DBM were implanted into each pouch. At week 4 implants 
were removed, and muscle and connective tissue were cleaned. Calcium content in each explant was measured by Arsenazo III Ca 
Assay. (Data represent the mean +/- SD, n = 15).
61
o 00 CN o
(jqSisM. Xip ;irejdx3 jo  jusDisd) umiojn^











stimulation of DBM was examined by histologic evaluation, which represents the 
traditional means o f monitoring biological activity. Equivalent amounts (20 mg) of DBM 
were implanted in muscle pouch sites. The implants were explanted at weeks 1,2, 3, and 
4, respectively. At day 7 (Figure 15a ) chondroblasts were observed around the DBM 
particles or in the old empty Haversian channels (or within crevices o f DBM particles).
At day 14 (Figure 15b) while some chondroblasts still remain, some o f them have 
become hypertrophic chondrocytes and osteoblasts can be seen at this stage. At day 21 
(Figure 15c) few chondrocytes were observed and new woven bone was clearly evident. 
At day 28 (Figure 15d), osteoblasts had secreted matrix and differentiated osteocytes 
were visible. New bone formation and bone marrow were visible along the edges of old 
bone, as were the vascular vessels at week 4. Most cartilage was replaced by new bone by 
week 4. A section of unimplanted DBM is shown in Figure 15e, where dead bone is 
indicated by the empty lacunae and Haversian channels.
1.4 Alkaline Phosphatase Activity in the In Vivo Bioassay.
Alkaline phosphatase was used as one of the biochemical indicators of 
osteoinduction in the in vivo model, where high levels of alkaline phosphatase activity 
were considered to be a characteristic of osteoblasts. In this study DBM (20 mg) and 
nonDBM (20 mg, used as control) were randomly implanted into muscle pouches of each 
athymic mouse. The ALP activities of the cells which had migrated into the DBM and 
nondemineralized bone matrix implants were assayed on days 2 ,4 ,6 , 8 ,10,12 and 14, 
respectively.


















Figure 15. Development stages of new bone formation induced by DBM. Hematoxylin-eosin staining. (lOx) a) Week 1 of 
implantation. Mesenchymal cells are seen in opposition to implanted demineralized bone matrix showing chondroblast-like 
morphology, b) Week 2 of implantation. Chondroblasts, chondrocyte and calcified cartilage are shown, c) Week 3 of implantation. 
Cartilage is gradually replaced by new bone, small amount o f new bone formation, bone marrow is visible, d) Week 4 of implantation. 
Cartilage almost replaced by new bone, large amounts of new bone formation. Arrows indicate the new bone, e) A section of 
unimplanted demineralized bone matrix, where dead bone is indicated by the empty lacunae and Harversion channel.
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As shown in Figure 16, within the first 6 days following implantation of 20 mg 
aliquots of DBM there were no significant increases in ALP activities (P > 0.05). From 
day 6, however, ALP activity started to increase and by day 14 the ALP activity 
approximated 402 enzyme units, which is 104 times that of the ALP of equivalent control 
explants (20 mg nonDBM) (3.86 enzyme units).
ALP activity assayed at day 14 (2 weeks) of the in vivo assay was thus chosen as 
an additional indicator for osteoinductivity of DBM in addition to the in vivo 
remineralization assay.
1.5 Time Course of Remineralization of DBM in the In Vivo Model
In order to find the best time for the in vivo bioassay of DBM, equivalent amounts 
(20 mg) of DBM were implanted into muscle pouches and remineralization of implants 
were assessed at weeks 1,2, 3,4, and 5, respectively. Remineralization, i.e calcification, 
is used as an indicator of osteoinductivity of DBM because remineralization is the closest 
situation to clinical use.
As shown in Figure 17, before implantation the DBM contained 1.89 percent 
calcium of explant dry weight. After one, two, three, four and five weeks of implantation 
the calcium content of explants increased to 4.1 +/-0.73, 5.0 +/- 0.6, 7.0+/-1.3,10.8+/-0.4 
and 13.2+/-1.54 percent of explant dry weight, respectively. ANOVA analysis showed 
that the remineralization of week 1,2 and 3 explants was significantly higher than the 
residual calcium content of DBM before implantation, but there was no significant 
difference in remineralization among the explants from these three weeks (P > 0.05).

















Figure 16. The time course of APase activity in the in vivo assay. Equal amounts of DBM (20 mg) (♦-•$) were implanted into muscle 
pouches. Mice were sacrificed and implants were explanted at days 2 ,4 , 6, 8,10,12, and 14. Muscle and connective tissue were 
carefully cleaned and APase activities were measured according to the method described. Non demineralized bone matrix was used as 
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Figure 17. The time course of implant remineralization. DBM (20 mg) were implanted into muscle pouches and the implants were 
explanted at weeks 1,2, 3,4, and 5. Muscle and connective tissue around the explants were extensively cleaned. The explants were 
dried overnight at 90°C (Imperial II, Lab-line), dry weights of each explant were obtained and precisely recorded, the explants were 
then put into crucibles and ashed in a furnace for 24 hours. The calcium content in each explant were measured by Arsenazo III 
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Remineralization in the fourth week was significantly higher than that in the first three 
weeks (P < 0.05), there was no significant difference in remineralization between the 
explants from week 4 and week 5 of implantation (P > 0.05).
The weight change of implants during the 5 weeks of implantation was also 
determined. As shown in Figure 18,20 mg of DBM was implanted, after one week of 
implantation the implant weight was 18.25 +/- 2.7 mg. The weight of implants remained 
essentially constant for the next 3 weeks (from week 1 to week 4). From week 4 to week 
5 there is a dramatic increase in explant weight, reaching 26.5 +/- 0.4 mg. According to 
ANOVA analysis, week four is the best time to conduct the in vivo assay because during 
this time there is a significant increase in calcium content without an increase in implant 
weight.
Although the weights of implanted DBM remain constant during the first 4 weeks 
of implantation, the calcium content is continuously increasing, suggesting that a modest 
reabsorption process may be occurring. The calcium accumulation process in each 
implant is shown in Figure 19. At the time of implantation each DBM implant contained 
0.38 mg calcium, after explantation the calcium content increased to 0.73 (week 1), 0.92 
(week 2), 1.13 (week 3), 2.24 (week 4) and 3.51(week 5) mg per implant. The calcium 
deposition rate in implants remained constant during the first 3 weeks, at about 0.20 mg 
calcium per explant per week (or 0.028 mg calcium per explant per day). Starting from 
week 3 the calcium deposition rate became faster, increasing to 0.32 mg per implant per 
week (or 0.0457 mg per explant per day), which is almost 1.6 times higher than the rate 
for the first three weeks.
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1.6 In Vivo Dose-Response Study
A dose-response curve was studied as a way to determine the appropriate amount 
of DBM for implantation in the in vivo model. DBM (10,20, 30 or 40 mg) was 
implanted into muscle pouches and dissected out at week 4. Remineralization of implants 
was studied and the results are shown in Figure 20. Unexpectedly, the osteoinductivity 
did not demonstrate a positive relationship with the amount of DBM implanted. The 
highest osteinductivity level was obtained at 10 mg and 20 mg of DBM. The 10 mg of 
DBM provided for a remineralization level of 12.7 percent calcium of explant dry weight 
and the 20 mg of DBM provided for a remineralization level of 13.5 percent calcium of 
explant dry weight. Remineralization of 30 mg and 40 mg of DBM was 8.6 and 6.9 
percent calcium of explant dry weight, respectively, which is equal to 64% and 51.4%, 
respectively, of the maximum osteoinductivity found with the 20 mg of DBM. Based on 
these studies, 20 mg of DBM was chosen as the optimum amount of DBM to be 
implanted in the in vivo bioassay model.
1.7 Summary of the In Vivo Assay
The in vivo assay of osteoinductivity of human DBM in the athymic mouse model 
adheres to the following "rules":
1) Implantation in a muscle pouch causes less bleeding and tissue trauma and produces 
high levels of remineralization, and was chosen as the implantation site for use in the in 
vivo bioassay.
2) Four weeks after implantation the DBM is sufficiently remineralized to provide for

















Figure 20. In vivo dose-response study. DBM was (10 , 20, 30 and 40 mg) implanted into muscle pouches and calcium contents 
assayed at week 4. Data represent the mean +/- SD (n = 3).
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statistically significant levels of remineralization and was chosen as the time for the 
measurement of calcium content (remineralization) of implant.
3) The amount of DBM to be implanted was set at 20 mg (dry weight) in that this 
quantity of biomaterial produced the highest levels of osteoinductivity.
4) Two weeks post-implantation represents an appropriate time for the measurement of 
alkaline phosphatase activity in the explanted implant. This time interval provides for a 
statistically significant increase in ALP activity.
2. ESTABLISHMENT OF THE IN  VITRO BIOASSAY MODEL
2.1 Initiation and Characterization of HPO/CB-MZOl Cell Line
A human periosteal cell line was obtained using the outgrowth technique from the 
periosteum as described in the materials and methods. A master cell line was established 
by propagation of the primary cultured periosteal cell line to approximate passage 5. This 
cell line was designated HPO/CB-MZOl, and phenotypic characteristics were maintained 
over the course of this study by cryopreservation. All cells used in in vitro assays were 
from this cell line.
HPO/CB-MZOl cells were used in the in vitro bioassay of DBM. In bone repair it 
has been suggested that osteoblast progenitor cells migrate from the periosteum, 
differentiate into osteoblast cells which in turn contribute to the formation of new bone 
(Ham and Harris, 1956).
The morphologic pattern of HPO/CB-MZ cells in cell culture is shown in Figure 
21. Cultured in the minimum essential media (Sigma) supplemented with 10% FBS, the
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periosteal cells exhibited spindle and stellate shapes with fine homogeneous cytoplasm, 
typically associated with fibroblast-like cells. The most distinguishing characteristic of 
the cell line is the long processes. When confluent, as shown in Figure 22, HPO/CB- 
MZOl cells were aligned in orderly fashion and showed a regular confluent pattern where 
some areas have high cell density and some areas have lower cell densities.
2.2 Proliferation Effects of DBM in the In Vitro Assay
The proliferation effect of DBM on the HPO/CB-MZOl cells was studied as a 
means o f assessing mitogenicity. To study induced proliferation by DBM, periosteal cells 
were seeded at 6.25 X 105 cells/T-25 flask and maintained in alpha-MEM supplemented 
with 10% FBS and antibiotics for 5 days. After a media change to DMEM supplemented 
with 2% FCS and antibiotics, 5 mg of DBM were added into each flask (day 0). Cell 
numbers were counted daily (for 5 days) using a hemocytometer.
After 5 days of maintenance in MEM cell number increased from the seeding 
density o f 6.25 x 10VT-25 flask to about 1.39 x 106 cells/T-25 flask. As shown in Figure 
23, after changing to DMEM, the cell numbers in the control flasks (without DBM) 
fluctuated around the density of 1.39 X 106 cells/T-25 flask. In the DBM treated flasks, 
the cell numbers increased to 1.70 X 106 per T-25 flasks, and stayed at this density for 
two days (days 4 and 5), which is significantly higher than the controls (P < 0.05). There 
is no significant difference between the DBM treated and control cells during the first 3 
days of incubation (P > 0.05).
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Figure 23. Mitogenic effects of DBM on HPO/CB-MZOl cells. Cells were incubated with assay media and DBM( 5 mg/T-25 flask), 
control flasks lacked DBM. Cell numbers in each flask were counted each day over the five day experimental period. Data represent 
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2.3 Morphologic and Histochemical Studies of the Effects of Demineralized Bone 
Matrix on the HPO/CB-MZOl Cells
Morphologic and histochemical changes under the influence of DBM were 
studied by setting up the assay as follows: HPO/CB-MZOl cells were seeded at 6.25 X 
105 cells/T-25 flask and maintained in alpha-MEM supplemented with 10% FBS and 
antibiotics for 5 days. After a media change to DMEM supplemented with 2% FCS and 
antibiotics, 5 mg of DBM were added into each flask. The day when DBM was added 
was defined as day 0.
In the morphologic studies, all photographs were taken on day 5. The control 
cells (without DBM) are shown in Figure 24a. In the control flasks the cells possess a 
spindle shape and are arranged in a regular confluent pattern, with some areas showing 
low cell densities and some areas showing high cell densities. After 5 days of incubation 
there was not much extracellular matrix secreted by the control cells. The cells incubated 
with DBM for 5 days are shown in Figures 24b and 24c. There were some visible 
morphologic changes in those DBM treated cells. The DBM treated cells appeared 
shortened and flattened, and were surrounded by extracellular matrix. The regular 
confluence pattern was disturbed ( Figure 24b). Having the ability to secrete extracellular 
materials is a phenotype associated with osteoblasts. Cells were frequently observed to 
retract from the area covered by the extracellular matrix (Figure 24c).
Alkaline phosphatase activity was studied by FVR-Hematoxylin staining. The 
results are shown in Figures 25a through 25c. The histochemical studies revealed that the

















Figure 24. Morphology study of the effects of DBM in the in vitro bioassay (xlO). a) Control cells. HPO/CB-MZOl cells were 
incubated in DMEM assay media for five days, b) DBM treated cells. HPO/CB-MZOl cells were incubated with DBM ( 5 mg/T-25 
flask) and DMEM assay media for 5 days, c) DBM treated cells. Cells were treated same as b). Cells retracted from some areas which 
are covered with extracellular matrix.
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Figure 25. Alkaline phosphatase staining (Sigma kit) (xlO).a) Control cells. HPO/CB-MZOl cells were incubated with assay media for 
5 days. Blue staining color indicates low alkaline phosphatase activities in control flasks, b) DBM treated cells. HPO/CB-MZOl cells 
were incubated with DBM ( 5 mg/T-25 flask ) and DMEM assay media for 5 days. Dark purple staining color indicates very strong 
alkaline phosphatase activities in the high cell density areas, c). DBM treated cells. HPO/CB-MZOl cells were incubated with DBM 
(5 mg/T-25 flask ) and DMEM assay media for 5 days. Purple staining color indicates high alkaline phosphatase activities in the low 
cell density areas.
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DBM can induce high alkaline phosphatase activities. The induced alkaline phosphatase 
activities were not only observed in the cells which had a direct contact with DBM 
particles, but also in the cells which had no direct contact with DBM particles. In the 
control flasks (Figure 25a), both the low and high cell density areas were stained blue, 
indicating low levels of alkaline phosphatase activity. In the DBM treated flasks a strong 
purple color appeared in the high cell density area (Figure 25b) and the low cell density 
areas (Figure 25c), indicating very high alkaline phosphatase activities.
2.4 Soluble Factors in DBM
This study was designed to see if the osteoinductive factors, BMPs or other 
factors, represent a soluble component of DBM such that it becomes distributed into the 
media in the in vitro bioassay flasks. DBM was soaked in assay media for a month in 
the refrigerator after which the soaking media and DBM were separated and put into in 
vitro bioassay flasks to measure their ability to induce ALP activity. Untreated media 
without DBM were put into the control flasks. The induced ALP activities were assayed 
on day 5 after the treatment and the results are shown in Figure 26. The ALP activities 
induced by the soaking medium and soaked DBM were almost equal and significantly 
higher than the control cells (P < 0.05). On the other hand the ALP activities induced by 
both the soaked DBM and the soaking medium were lower than the ALP activities 
induced by the DBM plus medium treatment. It is suggested that there are soluble 
osteoinductive factors which can be dissolved from the DBM during the soaking.

















Figure 26. Solubility of demineralized bone derived factors in DBM. DBM were soaked in assay media for a month. The soaked 
media, soaked DBM, and DBM plus medium were separated and put into in vitro bioassay flasks for 5 days. The induced ALP 
activities were measured on day 5. Data represent the mean +/- SD (n = 3).
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2.5 Time Course of ALP Activity Changes in the In Vitro Bioassay
The osteoblast induction process is frequently monitored by measuring alkaline 
phosphatase activity. The changes of ALP level with time in the in vitro assays were 
studied with the objective of assessing the effects of DBM on osteoblast induction. 
Equivalent amounts of DBM (5 mg per T-25 flask) were added into each confluent cell 
culture. Control cell cultures did not receive DBM. ALP activities were assayed each day 
from day 1 to day 6 o f culture.
During the first 3 days of cell culture, ALP activities in the DBM treated cells did 
not increase (Figure 27). The control cells showed ALP activities of approximately 1.6 
enzyme units. The ALP activity of the DBM treated cells was approximately 1.1 
enzyme units during the first 3 days of incubation with DBM. Beginning from day 3, 
ALP activity in DBM treated cells started to increase, reaching 4.7 +/- 0.5 enzyme units 
at day 4, and 11.7 +/- 0.2 enzyme units at day 5. The latter ALP value is about 2.7 times 
greater than the ALP activities of the control cells on day 5. Two sample T-test analyses 
showed that the DBM treated cells had significantly higher ALP activities than the 
comparable control cells on both days 4 and 5 (P < 0.05). The ALP level of the DBM 
treated cells declined to a value of 5.5 enzyme units on day 6. According to this ALP 
time course, day 5 was chosen as the day for measurement of ALP activity in the in vitro 
bioassay.
2.6 In vitro Dose-Response Study.
An in vitro dose-response curve study was also conducted for the purpose of

















Figure 27. The time course of ALP activity in the in vitro assay. HPO/CB-MZOl cells were seeded at 6.25 X 105 cells/T-25 flask and 
maintained in alpha-MEM supplemented with 10% FCS, 100 units/ml penicillin and 50 pg/ml streptomycin for 5 days which was 
then changed to DMEM supplemented with 2% FBS , 100 units/ml penicillin and 50 pg/ml streptomycin. ALP activity was assayed 
at days 1 ,2 ,3 ,4 , 5 and 6 after the addition of bone matrix. Control flasks were treated with non-demineralized bone matrix. Data 
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determining appropriate amount of DBM for use in the in vitro bioassay. In the study, 
increasing amounts of DBM, i.e. 2, 5,10,20, 30 and 40 mg, were added into confluent 
cell cultures in T-25 flasks. Nondemineralized bone matrix (10 mg) was used as a control.
As observed in the in vivo dose-response study (Figure 28), there is no linear 
relationship between the osteoinductivity and the amount of DBM added. The addition of 
increasing amounts of DBM resulted in a peak of ALP activity (approximately 9.0 
enzyme units) in cultures receiving 5 to 10 mg of DBM. Cultures receiving 2, 20, 30, and 
40 mg of DBM exhibited significantly less ALP activity when compared to the cultures 
receiving 5 and 10 mg of DBM. In comparison with the highest ALP activity induced by 
5 mg of DBM, 10 mg provided 98% of the highest activity, 2 mg of DBM induced 59%, 
20 mg induced 39%, 30 mg induced 29%, and 40 mg induced 27% of the highest 
activity. The ALP activity of the control cells was 44% of the highest ALP activity, 
which was higher than the activity induced by 20,30 and 40 mg of DBM. These data 
suggest that there may be some inhibitory activity by larger quantities of DBM.
One way ANOVA analysis indicated that there was a significant difference among 
the treatment groups (P < 0.05). Fisher's multiple comparisons indicated that 5 mg and 10 
mg of DBM stimulated significantly higher ALP activity than other treatment groups.
The 2 mg DBM treatment group did not show a significantly higher ALP activity as 
compared to the control group. It is therefore suggested that 2 mg DBM/T-25 flask is not 
sufficient for use in the in vitro assay and 5 mg or 10 mg are the optimal amount(s) of 
DBM to be used. Based on these data, DBM doses of 5 mg per T-25 flask (or 0.5 mg/ml) 
of DBM were chosen for use in the in vitro assay in order to maximize the induction of

















Figure 28. In vitro DBM dose-response study. DBM (2, 5,10,20, 30 and 40 mg) were added into flasks of confluent HPO/CB-MZOl 
! cell. ALP activity were assayed at day 5. Data represent the mean +/- SD (n= 3).
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ALP activity.
2.7 Summary of the In Vitro Bioassay Model.
The in vitro bioassay of osteoinductivity of DBM using the HPO/CB-MZOl cell 
line was set to the following parameters:
1) Day 5 after addition of DBM to confluent cultures of HPO/CB-MZOl cells is the
optimal time for analysis of ALP activity. On day 5 the induced ALP reaches its
peak level.
2) The optimal amount of DBM to be used in the assay is 5 mg/T-25 flask. The 
amount used can fluctuate from 5 to 10 mg without significant influence on the 
activity of DBM. Quantities of DBM less than 5 mg or more than 10 mg should 
be avoided.
3. CORRELATION OF IN  VIVO AND IN VITRO OSTEOINDUCTIVITY ASSAYS
It is important to emphasize that the in vivo and in vitro assays measure inherently 
different events, but possess certain common features associated with the presumed 
response of cells to demineralized bone. The designation that a specific material is 
osteoinductive is revealed by the formation of bone in clinical applications. For purpose 
of this study, "osteoinductive" has been extended to include remineralization of human 
bone materials in an athymic mouse model system and stimulation of alkaline 
phosphatase activities in cultured human periosteal cells. Attempts at correlating these 
various assays of osteoinductivity should not be construed to imply that the DBM is
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having the same effect(s) in each assay. With the objective of correlating the in vivo 
remineralization assay and in vitro ALP assay, aliquots of samples o f DBM were 
divided into two parts. One part was used in the in vivo assay and the second part was 
used in the in vitro assay. The osteoinductivity of the in vivo assay was compared with 
the biological "osteoinductivity" of the in vitro assay. As shown in Figure 29, there is a 
strong indication (coefficient of determination R-square = 0.74) of a linear relationship 
between the ALP activity in the in vitro and remineralization in the in vivo assay 
suggesting that one assay is predictive of the second assay.
II. DONOR AND PROCESSING EFFECTS ON OSTEOINDUCTIVITY OF DBM
1. THE RELATIONSHIPS BETWEEN DONOR AND OSTEOINDUCTIVITY OF 
DERIVED DBM
1.1 Effects of Donor Age on Osteoinductivity of DBM
Demineralized bone matrices with residual calcium levels below 2% were 
generously provided by LifeNet Transplant Service. The DBM samples were divided into 
groups according to the donor age and gender as follows (number of sample in 
parentheses): 1) female < 20 years of age (n=3), 2) female 21-30 years of age (n=5), 3) 
female 31-40 years of age (n=4), 4) female 41-50 years of age (n=3), 5) female 51-60 
years of age (n=3), 6) male < 20 years of age (n=5), 7) male 21-30 years of age (n=4),
8) male 31-40 years of age (n=5), 9) male 41-50 years of age (n=5), 10) male 51-60 
years of age (n=6). DBM samples were randomly assigned to muscle pouches o f each 
athymic mouse. After 4 weeks of implantation the mice were sacrificed, implants were

















Figure 29. Correlation of the in vivo remineralization assay and the in vitro ALP activity assay. Equivalent amounts of DBM were 
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dissected out, and muscle and connective tissue were carefully removed from the 
explants. The calcium content of each explant was measured by Arsenazo III calcium 
assay.
1.2 Osteoinductivity as a Function of Male Donor Age
The effect(s) of male donor age on the osteoinductivity of derived DBM were 
expressed as a function of remineralization as shown in Figure 30. The data shown in 
Figure 30 suggest that osteoinductivity of DBM varies as a function of donor age. As 
indicated in Appendix A the bone from the male 41-50 years of age provided the 
maximum levels of osteoinductivity (12.6% calcium). This observation is consistent with 
the fact that males reach their peak bone density in middle age. DBM from the male 
donor age groups of 31-40, <20, and 21-30 produced remineralization levels of 9.7, 8.4, 
and 7.7 percent calcium of explant dry weight, respectively. After age 50 the bone mass 
of males typically begins to decline. Coincidently the osteoinductivity o f DBM from 
donors in the age group 51-60 produced a remineralization level of 7.2% calcium, which 
is significant lower than the osteoinductivity provided by the male age groups of 41-50 
and 31-40.
1.3 Osteoinductivity as a Function of Female Donor Age
The effect of female donor age on the osteoinductivity of DBM was analyzed and 
the data are shown in Figure 31. The highest osteoinductivity of DBM was noted in the 
female 31-40 age group (12.7% calcium)(Appendix B), which is about 10 years younger

















Figure 30. The effect of male donor age on the osteoinductivity o f DBM. DBM from different donors was grouped into the age groups
described and put into muscle pouches for four weeks. Remineralization of explants was measured using the Arsenazo III assay and
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Figure 31. The effect of female donor age on the osteoinductivity of DBM. DBM from female donors was grouped into each age groups
as described and put into muscle pouches of athymic mice. Remineralization o f DBM implants were measured at week 4 and expressed
as weight percent calcium of explant dry weight. Data represent the mean +/- SD.
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than the corresponding male group. This distribution is coincident with the fact that 
female bone mass reaches its peak in their early middle (31-40 years) age which is about 
5 to 10 years early than their male counterparts. Both male and female derived DBM 
produced highest levels of remineralization around 12-13% calcium in the in vivo 
bioassay.
DBM from female donors older than 40 showed a decline in osteoinductivity, for 
example, 10.1% remineralization for the 41-50 year age group and 7.7% remineralization 
for the 50-60 year age group. DBM from female donors younger than 20 years old 
produced a remineralization level of 9.3% calcium. The 21-30 age group produced a 
remineralization level of 7.04% calcium, which is significantly lower than the 
remineralization levels produced by the female donor age groups of 31-40 and 41-50.
The results of the above studies about the effect of age and gender were compared 
and are shown in Table 1. DBM from the female 31-40 age group produced the highest 
activity among all of the donor age groups tested (both male and female) and was 
assigned as 100% activity. DBM from the male 41-50 age group showed 
remineralization at 99% of the highest activity. The percent of the highest activity 
produced by DBM from other donor age and gender groups can be arranged from large to 
small as the following sequence: DBM from female 41-50 age group (80%), DBM from 
male 31-40 age group (76%), DBM from female < 20 age group (73%), DBM from male 
< 20 age group (66%), and DBM from female 51-60 age group and male 21-30 age group 
(61%), DBM from male 51-60 age group (57%), DBM from female 21-30 age group 
(55%). There was no record of any of the female donors exhibiting signs of osteoporosis.
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Table 1. In vivo bioassay of the effect of age and gender on the osteoinductivity of 
DBM (expressed as percent of the highest activity).




% o f  the highest 
activity ( male donor)
% o f  the highest 
activity ( fem ale  
donor
<20 8.4 9.3 66 73
21-30 7.7 7.04 61 55
31-40 9.7 12.7 76 100
41-50 12.6 10.1 99.1 80
51-60 7.2 7.7 57 61
1 Remineralization is expressed as weight percent calcium of dry bone powder.
1.4 Statistical Evaluation of Osteoinductivity of DBM Derived from the Different 
Donors
To further assess the effect of donor age and gender on osteoinductivity o f DBM, 
two way ANOVA analyses were performed. The results indicate that age has a large 
effect on osteoinductivity of DBM, while gender differences can be neglected. Two way 
ANOVA analyses indicated that there is a significant different among the age groups 
tested (P=0.0001), but there is no significant overall difference between the male and 
female within each age group (P=0.2971). However, there is a significant interaction 
between the age effect and gender effect (p=0.0210), i.e. as the age increases the gender
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factor (male and female) affects differently on the osteoinductivity. For example, DBM 
from the male 41-50 age group showed the highest osteoinductivity among the male 
donor age groups tested (Appendix A), while DBM from the female 31-40 age group 
showed the highest osteoinductivity among the female donor age groups tested 
(Appendix B). The overall comparisons of the effects of donor age and gender are shown 
in Figure 32. Scheffe multiple comparison test (Table 2) indicated that DBM from the 
31-40 and 41-50 age groups (both male and female) showed significantly higher 
osteoinductivity than DBM from all the other age groups tested, and there is no 
significant difference between these two age groups. DBM from the 21-30 and 51-60 age 
groups (both male and female) showed significantly lower osteoinductivity than DBM 
from all the groups tested, and there is no significant difference between these two age 
groups. DBM from the <20 age groups (both male and female) showed significantly 
higher osteoinductivity than DBM from the 21-30 and 51-60 age groups (both male and 
female), and significantly lower osteoinductivity than DBM from the 31-40 and 41-50 
age groups (both male and female). The comparisons for interaction indicated that there is 
no significant difference between male and female DBM in the age groups <20,21-30,
31 -40 and 51 -60, but there is a significant difference between the male and female DBM 
in the age group 41-50 (P = 0.0086).
In general, the major donor related effects are associated with donor age. DBM 
from donors in the 31-40 and 41-50 age groups (both male and female) produced the 
highest osteoinductivity, DBM from the < 20 age group (both male and female) produced 
the second high osteoinductivity, and DBM from the 21-30 and 51-60 age groups (both

















Figure 32. Comparisons of the effects of donor age and gender. DBM (20 mg) from donor age and gender groups as described was
implanted into muscle pouches of athymic mice. Remineralization of DBM implants were measured at week 4 and expressed as percent
calcium of explant dry weight. Data represent the mean +/- SD.
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male and female) produced the lowest osteoinductivity among all the age groups tested. 
The gender factor generally has no significant effects on osteoinductivity of DBM except 
in the age group of 41-50, in which the DBM from the male donor is significantly higher 
than DBM from the female donor (age 41-50).
Table 2. Statistical evaluation of the effect of donor age and gender on the 
osteoinductivity of DBM. Scheffe multiple comparison test. 
Comparisons for age. Probability level=0.05.
C w e d  gre ;s Probability value
<20 w l '-30' 0.0210
<20 w ith ' 0.0001
<20 with 41-^ v 0.0001
< 20 with 51-60 0.0324
21-30 with 31-40 0.0001
21-30 with 41-50 0.0001
21-30 with 51-60 1.0000
31-40 with 41-50 0.9618
31-40 with 51-60 0.0001
41-50 with 51-60 0.0001
1. <  20 with 21-30 means that the osteoinductivity produced by DBM  from the age group <  20 (both male and 
fem ale) was compared with the osteoinductivity produced by DBM  from the age group 21-30  (both male and 
fem ale). The compared result was indicated by P =  0.0210, which is less than 0.05, so there is a  significant 
different between these tw o age groups.
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2. THE EFFECT OF RESIDUAL CALCIUM ON THE OSTEOINDUCTIVITY OF 
DBM
2.1 Preparation of DBM With Different Levels of Residual Calcium
Ground bone matrix with a size range from 250 micron to 710 micron was 
obtained from LifeNet Transplant Service and demineralized in 0.5 N HC1 solution. 
Differentially demineralized DBM was obtained by removing bone matrix at 45 minute 
intervals, i.e., 45, 90,135,180 minutes, and then 300 minutes (prolonged 
demineralization). The demineralized bone matrices were extensively washed and 
lyophilized. Residual calcium values in the differentially demineralized bone matrices 
were measured using the Arsenazo III calcium assay.
The residual calcium levels in the DBM matrices and the pH changes during 
demineralization are shown in Figure 33 and Figure 34. Before demineralization the dry 
bone matrix contained 32.7 weight percent calcium. After 45 minutes of 
demineralization the pH of the demineralization solution was 2.4 (due to the buffering 
ability of the salts being solubilized from the bone matrix) and at this point the bone 
matrix contained a calcium content of 21%, i.e. 11.7% of the calcium was solubilized 
from the bone matrix. As the demineralization process continued the buffering capacity 
of dissolved salts decreased and by 90 minutes of demineralization the pH dropped to
1.04 and calcium content of the bone matrix was 8.9%, i.e. another 12.1% drop in 
calcium content. Beyond 90 minutes of demineralization the buffering ability of salts 
dissolving from DBM was almost lost and the pH of the eluent solution remained at 
approximately 1.0. At 135 minutes the pH was still 1.04, while the calcium content of the

















Figure 33. Change of pH of the demineralized solution during the demineralization process. Bone matrices were demineralized in 0.5 













































Figure 34. Residual calcium levels in. ground bone particles within the size range of 250 to 710 microns versus demineralization time 
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bone matrix dropped to 2.2%. At 180 minutes the pH was 0.78 and the calcium content 
of the bone matrix remained at 2.0%. Following prolonged demineralization (300 
minutes) the pH value was 0.65 and calcium content o f the bone matrix was 1.2%.
In general, before the residual calcium content of bone matrix reaches 
approximately 2.0% the demineralization process proceeds rapidly and most of the 
mineral content of ground bone is demineralized before this point. Beyond this point the 
demineralization process occurs more slowly with more moderate changes in residual 
calcium contents. Consequently, 2.0% residual calcium in DBM may be quickly and 
easily achieved and, as will be demonstrated in this study, may be considered to represent 
the end point of the demineralization process.
2.2 In Vivo Bioassay o f the Effect of Residual Calcium on Osteoinductivity
The effect of residual calcium content on the osteoinductivities of DBM was 
assessed using both the in vivo and in vitro bioassay models. In the in vivo model, 
equivalent amounts (20 mg) of bone matrix, with different residual calcium levels, were 
implanted in muscle pouch sites in athymic mice. Samples were randomly assigned to 
muscle pouches and mice. After 4 weeks of implantation the implants were explanted 
and cleaned of muscle and connective tissue. Calcium levels were assayed using the 
Arsenazo III calcium assay. Remineralization was expressed as percent calcium of 
explant dry weight and normalized by calculating the change in weight percent calcium 
of each explant.
As shown in Figure 35, nondemineralized bone matrix not only did not exhibit

















Figure 35. Changes in percent residual calcium of implanted bone particles containing variable levels of residual calcium at the time of 
implantation. Demineralized bone matrices (20 mg) containing different levels of residual calcium were implanted into muscle 
pouches for four weeks, explanted and assayed for remineralization, i.e. weight percent calcium of explant. The percent residual 
calcium at the time of implantation is shown on the X-axis and the change in percent residual calcium at the time of explantation is 
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any remineralization, it actually decreased (-2.6%) in calcium content. This loss in 
calcium is probably due to a resorption/remodeling process on the bone matrix after 
implantation. Slightly demineralized bone, i.e. bone matrix containing 21% residual 
calcium, provided for DBM exhibiting a degree of remineralization, i.e. a 4.1% increase 
in calcium content.
There is a mixed relationship between residual calcium content and 
osteoinductivity of DBM. As the residual calcium content in DBM decreased from 21% 
to 2% the explant remineralization increased. For example, bone matrix containing 8.9% 
residual calcium at the time of implantation showed a 5.5% increase in weight percent of 
calcium, bone matrix with 2.2% residual calcium showed a increase of 6.9% calcium, 
and bone matrix with 2.0% residual calcium at the time of implantation showed the 
highest degree of remineralization, 7.9% calcium. The relationship between residual 
calcium and osteoinductivity can be expressed as : Y = -0.28 X + 8.34 (R2=0.7694), 
where Y is the percent calcium of explant dry weight, and X is the residual calcium level 
of implanted DBM. This relationship applies to DBM containing residual calcium to 
levels between 21% and 2%.
Prolonged demineralization produced DBM with low levels of residual calcium 
(1.2%), but did not provide bone matrix with increased osteoinductivity. Instead, DBM 
demineralized to calcium levels less than 2% residual calcium provided for matrix 
exhibiting a decrease in remineralization ( increase of 5.1% calcium at explantation).
To further normalize and compare the osteoinductivity of variously demineralized 
DBM, the concept of percent of highest osteoinductivity is introduced. As shown in
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Table 3, the highest osteoinductivity (remineralization) was achieved by bone matrix 
implants containing 2% residual calcium at the time of implantation. The 2.2% residual 
calcium bone matrix achieved 87% of the highest activity, the 8.9% residual bone matrix 
achieved 70% of the highest activity, the bone matrix demineralized to 1.2% calcium 
showed 65% of the highest activity, and the 21% residual calcium bone matrix produced 
52% of the highest activity. The non DBM did not remineralize in this assay.
One way ANOVA analysis indicated that there were significant differences in the 
osteoinductivity among DBM with different levels of residual calcium (P=0.0003). As 
shown in Table 4, Fisher's multiple test indicated that all demineralized bone matrices 
(residual calcium content from 21% to 1.2%) demonstrated a significantly higher 
osteoinductivity than nondemineralized bone matrix with a residual calcium content of 
32.7%. Bone matrix containing 2% residual calcium has a significantly higher 
osteoinductivity value than bone matrix containing 21% residual calcium. There are no 
significant differences among the osteoinductivities of the other residual calcium groups 
of DBM (P>  0.05).
In general, the residual calcium levels of DBM significantly affected 
osteoinductivity. Nondemineralized bone matrix is not osteoinductive, and as the mineral 
content decreased towards 2% residual calcium the osteoinductivity of bone matrix 
increased. The 2% residual calcium implants produced the optimum osteoinductivity. 
Prolonged demineralization of DBM appears to damage the osteoinductive ability of 
DBM.
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Table 3. The effect of residual calcium on the osteoinductivity of human DBM.
T im e1 pH2 Percent residual 
calcium3
% o f  the highest activity in 
vivo
% o f  the highest activity in 
vitro
Blank — — — 53
0 — 32.7 0 56
45’ 2.4 21 52 70
90' 1.04 8.9 70 78
135' 1.04 2.2 87 —
180' 0.78 2 100 100
300' 0.65 1.2 65 70
1 T im e represents the demineralization time.
2 pH represents the pH values o f  the demineralization solution at the time the bone sample was removed from the 
demineralization process.
3 Percent residual calcium is presented as a calcium weight percent o f  the dry w eight o f  bone matrix.
Table 4. Statistical evaluation of the effect of residual calcium of human DBM on 
the osteoinductivity ( in the in vivo model). Fisher's multiple comparison 
results. Probability Level: 0.05
1 Set 1: 32.7%2
Set 2: 21%, 8.9%, 1.2%, 2.2% 
Set 3: 8.9%, 1.2%, 2.2%, 2.0%
1 Set is a term used in Fisher's multiple comparison. The residual groups which showed no significant difference 
in their osteoinductivity were arranged in the same set. There is a  significant difference among the residual 
calcium  groups which appear in different sets.
2 This number represents the residual calcium group tested in the in vivo bioassay.
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2.3 In Vitro Bioassay of the Effect of Residual Calcium on Osteoinductivity
The in vitro bioassay was also used as to assess the effect of residual calcium 
levels on the osteoinductivty of DBM. Equivalent amounts (5 mg) of DBM with different 
levels of residual calcium were randomly put into T-25 flasks containing confluent 
HPO/CB-MZOl cells. ALP activities were assayed on day 5 after the DBM treatment, 
and the results were compared and shown in Figure 36.
As described in the in vivo assay, nondemineralized bone matrix did not provide 
for increases in ALP activity in the in vitro assay when compared to the control cells. All 
demineralized bone matrices, irrespective of the levels of residual calcium, demonstrated 
an increase in ALP activities in the in vitro bioassay. As shown in Figure 36, as the 
residual calcium content in DBM decreased the ability of the DBM to induce ALP 
activity increased. DBM with 21% residual calcium provided for the lowest level of ALP 
activity and the 2% residual calcium DBM provided for the highest ALP activity. DBM 
with residual calcium values greater than and less than 2% residual calcium provided for
lower levels of ALP activity indicating a decrease in the potential for osteoinductivity.
The osteoinductivity of variously demineralized bone matrices was calculated as a
percentage of the most osteoinductive matrix and the results are shown in Table 3. DBM 
containing 2% residual calcium showed the highest osteoinductivity. DBM containing
8.9% residual calcium provided for 78% of the highest activity (which is almost at the 
same level as in the in vivo bioassay). DBM containing 1.2% and 21% residual calcium 
provided for 71% and 70%, respectively, of the highest ALP activity. Nondemineralized 
bone matrix and control cells produced almost equal percentages of the highest ALP

















Figure 36. Alkaline phosphatase levels in HPO/CB-MZOl cells cultured in the presence of demineralized bone particles containing 
variable levels of residual calcium. Cells were incubated with assay media and bone matrix (5  mg/T-25 flask) , ALP activities were 
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activity, 53% and 56%, respectively.
ANOVA analysis indicated that there are significant differences among the ALP 
activities induced by the demineralized bone matrices with different levels of residual 
calcium (P = 0.0027). Fisher's multiple comparisons (Table 5) showed that 2% and 8.9% 
residual calcium bone matrix induced significantly elevated levels of ALP activity when 
compared to control cells. There is no significant difference among the ALP activities 
induced by the residual calcium groups of 32.75%, 21%, 1.2% and control cells.
In general, in vitro bioassays confirmed the results found the in vivo assays in that 
residual calcium levels do have a significant effect on the osteoinductivity of DBM. As 
the residual calcium decreased the osteoinductivity of DBM increased. Prolonged 
demineralization of bone matrix to calcium levels less than 2% appear to diminish the
Table 5. Statistical Evaluation of the effect of the residual calcium content of DBM
on the osteoinductivity (in the in vitro model). Fisher's multiple comparisons. 
Probability level: 0.05.
1 Set 1: control, 32.7%, 21%, 1.2%2 
Set 2: 21%, 8.9%, 1.2%
Set 3: 2%
1 Set is a term used in Fisher's multiple comparison. The residual calcium groups which showed no significant 
difference in their osteoinductivity were arranged in the same set. There is a significant difference among the 
residual calcium groups which appear in different sets.
2 This number represents the residual calcium group tested in the in vitro bioassay.
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ability of DBM to stimulate the HPO/CB-MZOl cells to produce elevated levels of 
alkaline phosphatase.
3. The Effect of Particle Size on Osteoinductivity
3.1 Preparation of DBM of Different Particle Sizes
Sterile, freeze-dried nondemineralized bone blocks (generously provided by 
LifeNet Transplant Services) were grounded using a Tekmar impact grinder and sieved 
through a series of different sized sieves. Particle sizes <250, 250-355,355-500, 500-710 
and 710-850 micron were collected and demineralized in 0.5 N HC1 for identical time 
periods at the same acid to bone matrix ratio (20 ml acid : 200 mg bone matrix). Sterile 
demineralized bone matrices were lyophilized and stored under vacuum until used in 
experiments. Residual calcium levels of DBM were measured using the Arsenazo III 
calcium assay.
Residual calcium levels present in the different particle size groups were 
compared and the results are shown in Figure 37. As a general rule, when ground bone 
is demineralized under equivalent conditions smaller size particles are more extensively 
demineralized than larger size bone particles. This effect may be attributable to a greater 
surface area to volume ratio as particle size decreases and more contact with acid 
solution. The 710-850 micron particle size group contained the highest levels of residual 
calcium among the five particle size groups. The 355-500 and 500-710 micron particle 
size groups contained the second highest, and equal amounts, of residual calcium content.
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The 250-355 particle size group showed lower residual calcium levels and particle size 
less than 250 micron showed the lowest levels of residual calcium.
3.2 In vivo Bioassay of the Effect of Particle Size on Osteoinductivity
The effect of particle size on osteoinductivity of DBM was assessed using both the in 
vivo and in vitro bioassay models. In the in vivo assay, equivalent amounts of DBM (20 
mg) with different particle size were randomly assigned into muscle pouch sites of 
athymic mice. After 4 weeks of implantation the athymic mice were sacrificed, implants 
were dissected out and calcium contents were assayed using the Arsenazo III assay.
The effects of particle size on osteoinductivity were compared and the results are 
shown in Figure 38. Different particle sizes have different effects on osteoinductivity. 
Demineralized bone particles in the 500-710 micron particle size range provided for the 
highest remineralization (6.7% calcium). DBM in particle sizes 710 micron to <250 
micron decreased in the osteoinductivity as particle size decreased. An interesting 
finding was that although bone particle sizes 500-710 and 355-500 micron have 
equivalent amounts of residual calcium, they did not show equal osteoinductivity. DBM 
in the particle size range 500-710 micron has a  significantly higher osteoinductivity than
DBM particles in the 355-500 micron size range. On the other hand bone particles in the 
size groups 355-500 micron and 250-355 micron contained different levels of residual 
calcium content at implantation, yet showed equal levels of remineralization. These 
results indicate that the particle size has an effect equal to or greater than residual calcium 
content on osteoinductivity of DBM. Weight changes (Figure 39) in implanted DBM

















Figure 38. The effect of particle size on the remineralization of implants in the in vivo bioassay. Demineralized bone matrix with
different particle sizes were implanted into muscle pouches for four weeks. The calcium content accumulated in each explant were
measured by Arsenazo III and expressed as weigh percent calcium of explant. Data represent the mean +/- SD (n = 3).
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during the 4 weeks of implantation revealed that explants from the 250-355 micron and 
<250 micron particle size groups provided for greater weight loss than observed for the 
larger particle size groups.
To further normalize and compare the osteoinductivity of DBM versus particle 
size, the percentages of the highest osteoinductivity were calculated (Table 6 )  and 
compared. The 500-710 micron particle size range produced the highest osteoinductivity. 
The osteoinductivity demonstrated by other particle size groups can thus be arranged, 
from high to low, as the following: 710-850 micron size group (73%), 355-500 and 250- 
355 micron group (63%), <250 micron group (35%).
ANOVA analysis indicated that there were significant differences among the 
remineralization induced by the different particle size groups (P = 0.0004) in the in vivo 
bioassay. Fisher's multiple comparisons (Table 7) indicated that the DBM particle size 
500-710 micron has a significantly higher osteoinductivity than DBM from all the other 
size groups (710-850, 355-500,250-355 and < 250 micron). The <250 micron group has 
a significantly lower osteoinductivity than DBM from all the other size groups ( 710-850, 
500-710,355-500 and 250-355 micron). There is no significant difference among the
remineralizations induced by DBM from the bone particle size groups 355-500 micron, 
250-355 micron and 710-850 micron.
In general, particle size has a significant effect on the osteoinductivity of DBM. 
Under identical conditions of demineralization the 500-710 micron particle size provided 
for the highest osteoinductivity. Particles smaller and larger than 500-710 micron 
provided for lower estimates of osteoinductivity.

















Figure 39. Explant weights at the time of explantation as a function of bone particle size range at the time of implantation. DBM (20
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3.3 In Vitro Bioassay of the Effect of Particle Size on Osteoinductivity
The in vitro bioassay was also used to study the effect of DBM particle size on 
osteoinductivity of DBM. Equivalent amounts of DBM (5 mg) were randomly put into 
T-25 flasks containing confluent cultures of HPO/CB-MZOl cells. Control cells did not 
receive DBM. DBM-containing and control cell cultures were incubated at 37°C in a 5% 
C 02 incubator and the induced ALP activities were assayed on day 5.
The ALP activity induced by different particle size DBM and control cells in the 
in vitro assay were compared and shown in Figure 40. DBM in the 500-710 micron 
particle size range provided the highest levels of alkaline phosphatase. From 710 micron
to < 250 micron, as particle size decreased the ability to induce ALP activity decreased. 
The 355-500 micron and 250-355 micron particle size groups exhibited equivalent levels 
of activity as observed in the in vivo assay. The < 250 micron and the 710-850 micron 
particle size groups produced the lowest, and almost equal amounts of ALP activity 
among the five size groups tested.
In the in vitro bioassay the 500-710 showed the highest osteoinductivity among 
the size groups tested (Table 6). The smaller size, for example 355-500,250-355 and < 
250 micron groups, provided for higher percentages of the highest activity (73%, 71% 
and 43%, respectively) than their in vivo bioassay (63%, 63% and 35%, respectively).
The large particle size (710-850 micron group) showed a lower percent of the highest 
activity (50%) than the in vivo assay (73%).
ANOVA analysis (Table 8) indicated that there were significant differences 
among the ALP activities induced by the different particle size groups (P = 0.0003).
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Table 6. In vivo and in vitro bioassay of the effect of particle sizes on osteoinductivity 
(expressed as the percent of the highest activity).
‘Size (micron) 2W eight o f  
explant (m g) in vivo
% o f  the highest activity in 
vivo
% o f  the highest activity in 
vitro
710-850 17 73 50
500-710 17 100 100
355-500 16 63 73
250-355 12 63 71
<250 7 35 43
1 Size represents the size groups tested in the in vivo and in vitro bioassays.
2 The explant weight (dry weight) is measured after 4  w eeks o f  implantation.
Table 7. In vivo bioassay of the effect of particle size on osteoinductivity. 
Fisher's multiple comparisons. Probability level: 0.05.
1 Set 1: <250 micron2
Set 2: 355-500 micron, 355-250 micron, 850-710 micron 
Set 3: 500-710 micron
1 Set is a term used in Fisher's multiple comparison. There is no significant differences am ong the size groups 
which appear in the same set. There is a significant difference among the size groups which appear in different 
sets.
2 The size  group represents the size group tested in the in vivo and in vitro bioassays.

















Figure 40. Alkaline phosphatase levels in HPO/CB-MZOl cells incubated in the presence of ground demineralized bone particles of 
variable particle size. Cells were incubated with bone matrix with variable particle sizes and assay media for five days. The ALP 
activities were assayed on day five and expressed as enzyme units. Control cells were not exposed to DBM over the 5 days of 
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Fisher's multiple comparisons indicated that all the size groups, except the <250 micron 
size group, provided significantly higher levels of ALP than the control group. In 
addition, DBM in the 500-710 micron particle size groups provided for significantly 
higher ALP levels than all other DBM bone particle size groups tested.
In general, the in vitro assay data were consistent with the in vivo assay data, and 
confirmed that the DBM particle size range 500-710 micron provided for the highest 
osteoinductivity. The DBM particle size 355-500 micron and 250-355 micron showed 
equivalent amounts of osteoinductivity, the DBM particle size range < 250 micron 
showed the lowest osteoinductive activity.
Table 8. Statistical evaluation of the effect of particle sizes on the osteoinductivity 
(in the in vitro model). Fisher's multiple comparisons. Probability level: 0.05.
1 Set 1: Control, <250 micron 
Set 2: <250 micron, 850- 710 micron 
Set 3: 500-355 micron, 355- 250 micron 
Set 4: 710-500 micron
1 Set is a term used in Fisher's multiple comparison. There is no significant difference am ong the size groups 
which appear in the same set. There is a significant difference among the size groups which appear in different 
sets.
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Historically autogenous bone grafts have been most widely used in orthopaedic 
applications and still remain the gold standard for bone graft materials used for the 
enhancement of bony ingrowth. However due to second site morbidity and limited 
availability associated with the use of autograft bone, allograft bone has become an ideal 
choice for use in procedures where autograft tissue is normally used.
Demineralized bone (DBM), as a special form of allograft, is predominantly used 
in the form of a powdered or granular matrix. The mechanism underlying the clinical use 
of DBM is that this material can induce endochondral bone formation (Reddi et al., 
1972), most probably due to the existence of BMPs in these materials (Urist, 1979a), 
when implanted in the body. Because of the complex biologic processes associated with 
new bone formation, DBM remains an excellent choice for use in clinical applications.
In the past thirty years the osteoinductivity of demineralized bone and BMPs have 
been extensively studied in allogeneic animal models. The most commonly used 
experimental animals are mice, rats, rabbits and guinea pigs (Reddi et al., 1972; Huggins 
et al., 1970; Urist, 1965). However these animals are not a good choice for human DBM 
assessment because of "species specificity" reported by Reddi (Sampath et al., 1981). 
Marinak (1989) used a xenogeneic model to study the osteoinductive potential of human 
demineralized bone preparations and found that new bone formation was sparse within 
this xenogeneic system (Marinak et al., 1989). They indicated that the low yields of
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induced bone, in response to implants of human demineralized bone, would limit the use 
o f this model system in assessing osteoinductive potential prior to clinical use.
To overcome the species specificity problem, athymic mice were used in this 
current study and new bone formation was observed. This approach is similar to that 
described by Aspenberg in 1989 (Aspenberg et al., 1989). The new bone induction 
process in athymic mice follows an endochondral bone formation pathway as observed in 
allogeneic animal models, and the use of athymic mice as a xenogeneic animal model in 
ostoinductivity studies overcomes the problems of minimal new bone production due to 
species specificity and established a mean of assessing the quality of DBM prior to 
clinical use.
Two implantation sites, intramuscular and subcutaneous, have been reported 
(Urist, 1965; Reddi and Huggins, 1972; Reddi et al., 1976; Glowacki et al., 1981; 
Guterman et al., 1988; Bemick et al., 1989). Generally, intramuscular implantation 
provided higher osteoinductivity than subcutaneous implantation. This is the first study to 
compare the effect of implantation sites on osteoinductivity. This study demonstrated that 
intramuscular implantation provided a remineralization of 12.4 weight percent calcium 
after four weeks of implantation, while subcutaneous implantation only provided a 
remineralization of 1.6 weight percent calcium. Dohi and Sampath also reported 1 to 2 
% calcium remineralization in subcutaneous sites after a four-week implantation of DBM 
(Dohi et al., 1992; Sampath et al., 1992). It is not quite clear why intramuscular sites 
provided more remineralization than subcutaneous implantation. However, because of
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such a low level of osteoinductivity, the subcutaneous site may not be a suitable in vivo 
osteoinductivity assay model for DBM as also will be explained later. Histology studies 
indicated the presence of chondrocytes and cartilage formation between week 1 and week 
2 and the presence of osteoblasts, osteocytes and new bone formation between week 3 
and 4. This sequence of events is similar to embryo endochondral bone formation 
(Amenta, 1990), and a similar observation was reported by Reddi (Reddi et al., 1981).
The occurrence of elevated ALP activity is considered the earliest demonstrable 
osteogenic marker (Pitchard, 1972). ALP has been used as a diagnostic parameter for 
over 50 years as a marker of bone turnover in spite of the fact that its function in bone 
biology is still not completely clear. The assumption that ALP activity reflects mainly 
bone formation is based on the fact that the enzyme is expressed as a constitutive protein 
by osteoblasts, cells that are pivotal to bone formation. Based on the historical use and the 
stability o f this enzyme assay, ALP activity was used as a main indicator for bone 
formation in this study. The stability study of the enzyme indicated that ALP readily 
loses its activity with storage in the refrigerated or the frozen state.
In in vivo assay models day 12 is frequently picked as the day for ALP activity 
assay (Sampath, 1992; Reddi, 1981). In this study the change of ALP activity within the 
first 14 days of implantation was studied. The ALP activity showed small increase during 
the first 6 days of implantation and a large increases in ALP activity from day 6 to day 
14. At day 14 the ALP activity was almost 104 times that of the control cells. The peak of 
ALP activity was generally observed from day 12 to 15 after implantation (Nishimutu et 
al., 1985; Sampath et al., 1992). After about 2 weeks post implantation ALP levels start
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to decline (Dohi, 1992). The role of ALP in bone formation is not clear. High level ALP 
is always associated with new bone formation. ALP is considered to play a role in 
mineralization of new bone in that ALP can provide inorganic phosphate or inhibit 
inhibitors of bone mineralization (Wuthier, 1984).
Calcium content of explants is used as the major indicator of osteoinductivity in 
the present studies in that it closely approximates the expected clinical outcome. The 
method used in the determination of calcium content was the Arsenazo III method. 
Arsenazo III (2,2-[l,8-dihydroxy-3,6-disulpho-2,7-naphthalene-bis(azo)] dibenearsonic 
acid) is the method used largely in cellular and neurophysiological research to quantitate 
calcium and may replace the o-cresolphthalein complexone method in clinical diagnostic 
applications (Mullins et al., 1986; Smith et al., 1986; Femandez-Gavarron et al., 1987). 
The Arsenazo III assay is based on the fact that Arsenazo III forms a 1:1 complex with 
Ca+2 and other large metal cations, has a dissociation constant of 10'6 M, and a unique 
absorption peak at 655 nm (Sawin et al., 1961;). Using Arsenazo III, within-run 
precision (n = 20) was reported as low as 0.5 -1.2%, between-day precision was 1.1 - 
1.7%, and the coefficients of variation were around 1.5%, sometimes even lower than 1% 
(Rowatt et al., 1989). A similar range of within-run and between-day precisions of 
around 1.3% was previously reported by this laboratory (Homsi and Wolfmbarger 1993). 
This Arsenazo III method correlated well with the atomic absorption spectrophotometry 
method (r=0.981, P<0.05) (Homsi and Wolfmbarger 1993).
The times for the determination of explant calcium content in animals have varied 
from study to study (Marinak et al., 1989; Aspenberg et al., 1989; Forell et al., 1993;
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Sakano et al., 1993), complicating comparison of data. It is reported in this study that the 
highest calcium accumulation in implanted DBM occurred between week 3 and week 4. 
In the in vivo assay, week 1 to week 3 is the time of cartilage formation, calcification and 
initial new bone formation with a low rate of calcium deposition. This observation is 
similar to that reported by Reddi (Reddi et al., 1976) and Guterman (Guterman et al., 
1988). Most cartilage is replaced by new bone before week 3, as was also described in 
previous studies (Reddi et al., 1976; Guterman et al., 1988; Bemick et al., 1989). From 
week 4 to week 5 the explanted DBM exhibited a high rate of remineralization due to 
variable new bone formation. A similar observation was reported by Dohi (Dohi et al.,
1992). Week 4 represented the time of greatest remineralization and the best time for a 
quantitative assessment of new bone formation using the in vivo assay described herein.
The present study revealed that there is about a 4.1% increase in calcium content 
of DBM during the first week of implantation. According to the concurrent histology 
study, cartilage formation and calcification occur during the first week, which may 
account for the mineral content increase in the first week of implantation. However, it is 
also possible that the implanted bone collagen may induce the uptake of calcium and 
phosphate ions from the extracellular fluid, which may contribute to the increased 
mineral content observed. It is proposed that one of the steps in the mineralization of 
bone involves collagen as a nucleating agent (Katz, 1969). Katz's study indicated that the 
collagen matrix reduces by a factor of two the size of the nucleus needed for 
mineralization in the absence of matrix. A study by Jethi (1970) also indicated that 
collagen-containing fibers derived from beef tendon will induce the uptake of calcium
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and phosphate ions from stable solutions to form a matrix bound mineral phase. This 
observation may also explain concerns about the subcutaneous implantation model. As 
observed in this study, the subcutaneous explants only contained 1.6% calcium. If part of 
this calcification is due to the passive absorption of calcium by the matrix of DBM, then 
the reliability of the small quantity of calcification in the subcutaneous site in the 
reporting of osteoinductive potential is questionable.
DBM contains numerous growth factors, like epidermal growth factor (EGF), 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and BMPs 
(Hauschka et al., 1988). These growth factors and BMPs give DBM three basic 
characteristics: chemotactic, mitogenic and osteoinductive potential. Bone collagen is 
generally considered to serve as a scaffolding for bone formation (both osteoinduction 
and osteoconduction). However the role of old collagen and noncollagenous proteins 
from implanted DBM in promoting or accelerating mineralization in the osteoinduction 
process should not neglected. It has generally been agreed that collagen has the capacity 
to serve as a structural framework in tissue that is to undergo mineralization (Miller,
1968). Osteonectin, phosphoproteins, and noncollagenous matrix proteins have also been 
shown to be promoters of hydroxyapatite(HA) crystal deposition in vitro when in 
complex with collagen (Termine, 1981; Veis, 1978; Nawrot, 1976).
In vivo dose-response studies indicated that there is an inhibitory effect associated 
with high doses (30 and 40 mg) DBM. This observation is quite similar to what is 
observed with high doses of growth factors, like TGF-beta and FGF (Chen et al., 1991;
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Ber et al., 1991). The inhibitory effect of high dose DBM could come from its growth 
factor components (Hauschka et al., 1988). Based on these studies, it may be suggested 
that activities of DBM exhibit definite dependencies on the amount of DBM used. The 
reason for such dose dependency remains unknown at this time, but may be associated 
with too much or too little BMP, presence of inhibitory agents at higher DBM 
concentrations, increased/decreased micromotion of bone particle at the site of 
implantation in the in vivo assay, etc.
Because of the convenience of in vitro assays, the use of in vitro cell culture 
models was explored as a means of assessing the osteoinductive cell differentiation 
process and the osteoinductivity induced by DBM and associated BMPs. The cells most 
frequently used are osteoblasts (Takuwa et al., 1991; Thies et al., 1992; Sakano et al.,
1993). However, it seems inappropriate to use a differentiated cell line to assay the 
ability o f DBM to induce a differentiation process. Periosteal cells were used in the 
present study in that periosteal cells are presumed to be responsive to the actions of 
BMPs, differentiating into osteoblast cells. In bone repair, osteoprogenitor cells in the 
periosteum are the major source of cells migrating to the fracture site, where they 
proliferate and differentiate into chondrocytes and osteoblasts (Ham, 1956). It is still not 
clear where the mesenchymal cells associated with ectopic bone induction originate. 
However it is now generally accepted that undifferentiated osteoprogenitor cells are 
induced to migrate to implanted DBM.
The morphological study of periosteal (HPO/CB-MZOl) cells indicated a spindle
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and stellar shapes with fine homogeneous cytoplasm and long processes. A similar 
observation was reported by Teti (Teti et al., 1991). The proliferation effect of DBM on 
periosteal cells was observed. After a 5 day incubation with DBM the cell number 
increased about 1.3 fold in subconfluent cell cultures. Similar proliferation effects have 
been reported (Hauschka et al., 1988; Sampath et al., 1992). Hausechka found that DBM 
extracts can induced about a 1.5 fold increase in cell number, and Sampath reported 
human osteogenic protein 1 (hOP-1) induced about a 1.8 fold increase in cell number.
The proliferation effect(s) of DBM start after 3 days incubation with DBM, while DBM 
extracts and hOP-1 can induced cell proliferation after only 1 day of incubation. The 
delayed effect observed with DBM may be due to the slow release of growth factors and 
BMPs from DBM.
Under the influence o f DBM, cell confluence patterns were disturbed and the cell 
shape changed from an elongated shape to a more rounded shape. The shape changes 
occurred before the increases in ALP. Histochemical studies for ALP activity revealed 
that periosteal cells produced low levels of ALP. A similar observation was reported by 
Teti (Teti et al., 1991). After incubated with DBM the periosteal cells produced high 
ALP in the cells which were in direct and indirect contact with bone particles. This 
phenomenon implies that there are soluble factors in DBM which become dissolved in 
the media. This suggestion was confirmed by the “soluble factor study”. In this study the 
“soaking media” and “soaked DBM” induced almost equal amounts of ALP activity, 
which was almost half of the ALP activity induced by the positive control (media plus 
DBM).
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In the present in vitro assay, ALP activity peaks on day 5 after addition of DBM. 
This time represents a 2 day delay compared to what was observed with BMPs added to 
osteoblast cells in culture (Sampath et al., 1992; Thies et al., 1992). The delay may be 
due to the character of the cell line and the slow release of BMPs from DBM. In 
osteoblast culture, the effect of BMPs are to enhance the phenotype of the cell line while 
in periosteal cell culture it is to induce the differentiation process. This study showed that 
DBM can induce a 3 fold increase in ALP activity of human periosteal cells. Sampath and 
Thiest also reported about a 2 to 3 fold increase in ALP activity after the addition of hOP- 
1. In the in vitro dose-response study, 5 and 10 mg DBM were proved to be the optimum 
dose for the in vitro assay, with 20, 30 and 40 mg of DBM showing an inhibitory effect. 
The inhibitory effect may come from the greater amounts of growth factors released from 
the DBM.
The in vivo model is close to the clinical situation and appears to be a good model 
for assessment of the osteoinductivity of DBM. However, the experimental conditions are 
difficult to manipulate and control as compared to the in vitro assay model described. 
Correlation of "osteoinductivity" using the in vivo assay and the in vitro assay indicated a 
good correlation (R-square is 0.74). Thus, the in vitro model described in the present 
study may be a good substitute for the more traditional in vivo assay of osteoinductive 
potential of DBM.
The establishment of in vivo and in vitro bioassay models in the laboratory not 
only provided an opportunity to control the quality of DBM, but also makes it possible 
to evaluate the physical and chemical parameters used in the processing of DBM. The
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studies of the effects of residual calcium and particle size were used to validate the in 
vitro and in vivo assays of osteoinductivity and to assess specific aspects of the process 
used in the production of demineralized bone. Osteoinductivity (remineralization of 
implanted demineralized bone) was assessed following implantation of DBM in nude 
mice and induction of cell differentiation (as measured by changes in ALP activity) was 
assessed following addition of demineralized bone to cultures of human periosteal cells.
It was demonstrated that the percent residual calcium could be used to predict an optimal 
level of demineralization, such that bone which was under or over demineralized was 
clearly less osteoinductive. Available data suggest that ground bone demineralized to an 
approximate level of 2 percent residual calcium is optimal for the induction of new bone 
formation. It is thus essential that the demineralization process be monitored to ensure 
that ground bone is reproducible demineralized.
The results in this study showed that nondemineralized bone matrix is not 
osteoinductive, that slightly demineralized DBM provided a degree of osteoinductive 
activity, as the mineral content decreased the osteoinductivity increased, and that 
overdemineralized DBM can exhibit reduced osteoinductive potential. Similar results 
have been reported by Urist in the study of New Zealand rabbit bone (Urist, 1970). Urist 
found that low yields o f new bone were produced in implants of partially demineralized 
DBM preparations and high yields in implants of nearly or completely demineralized 
matrix. Urist suggested that old bone mineral delays the process of reabsorption and 
reduces the yields of new bone. Based on data derived in the present study, it is suggested
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that residual calcium has a big effect on osteoinductivity of DBM. Nondemineralized 
bone matrix did not induce remineralization in the in vivo study. DBM, nearly completely 
demineralized bone (with 2% residual calcium), provides for the highest 
osteoinductivity. Overly demineralized DBM (with 1.2% residual calcium) showed a 
lower osteoinductivity than DBM with 2% residual calcium. This reduction may be 
because of damage to BMPs resulting from the prolonged acid treatment or the removal 
of calcium phosphate nucleation sites in the form of hydroxyapatite cystals in the 
overdemineralized DBM..
The BMP hypothesis proposed by Urist (Urist et al., 1992) suggested that BMPs 
are released from a supramolecular aggregate of non collagenous proteins in the process 
of normal bone turnover or in response to injury or transplantation. The observation in 
this study, that the nondemineralized bone matrix showed no osteoinductivity, may be 
because o f the fact that the BMPs were bound or covered by the minerals, while 
demineralization will release BMPs. As more minerals were removed more BMPs were 
released from the DBM resulting in greater osteoinductivity.
BMPs are believed to be associated with nonsoluble, noncollagenous proteins 
during the regular demineralization process. However, in this study lower 
osteoinductivity was observed in the prolong demineralized group, suggesting that BMPs 
could be dissolved or damaged in the process of demineralization.
Additional data presented in this study demonstrate that bone particle size has a 
dramatic effect on the osteoinduction process. Bone particles between 500 microns and
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710 microns appear to represent the optimal size range in that bone particles of larger or 
smaller sizes remineralized to a lesser extent in the in vivo assay and stimulated lower 
alkaline phosphatase activities in the in vitro assay. Similar results have been reported by 
other authors (Vail et al., 1994). Vail found that equine matrix particle sizes o f 2.0 mm3 
and 5.0 mm3 were associated with osteoinductive activity and minimal signs of local 
inflammation. The two smaller particle sizes (0.425 mm3 to 0.850 mm3 and 0.850 mm3 to 
2.000 mm3) were minimally osteoinductive and were associated with a greater local 
inflammatory response. Sampath and Reddi (1984) also reported on the importance of 
geometry of the extracellular matrix in endochondral bone differentiation. They found, 
in agreement with what we observed here, that fine particles did not induce bone 
formation. It is suggested that resorption of fine particles after implantation is a very 
important factor responsible for the lower bone induction observed in this and other 
studies. Small particles generally produced a high percent of the highest activity in the in 
vitro bioassay, where resorption did not play a role. In the in vivo bioassay, where 
reduced explant weight was observed, the smaller particle sizes of DBM were less 
osteoinductive. Thus, it is very possible that small particles may still possess high 
osteoinductive potential, however the resorption process reduces the amount o f DBM 
available and therefore reduces the osteoinductivity of the DBM (Sampath and Reddi, 
1984).
Additional factors must be considered in assessing the respective roles of bone 
particle size in both the in vivo and in vitro assay. It was demonstrated in the present 
study that demineralization of ground bone containing a range of particle sizes results in 
variable levels o f demineralization. Smaller bone particles are more extensively
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demineralized than larger bone particles within a given time interval. Thus, within a 
specified sample of ground demineralized bone, the percent residual calcium represents 
an average level of demineralization. Future investigations will need to consider the role 
of both particle size and percent residual calcium in the osteoinductive potential of the 
DBM produced. It is emphasized that the data in the current study regarding percent 
residual calcium and subsequent osteoinductivity should not be construed to suggest that 
percent residual calcium is the sole determinant of osteoinductivity.
The bone mass of humans is constantly changing with age. Before 30 years of 
age the bone is not mature and bone mass is increasing as aging increases. Bone mass 
reaches its peak in middle age, i.e from 31 to 50, and then starts to decline. The current 
study on the effect of donor age and gender revealed that the donor age has a fundamental 
effect while die gender factor did not show significant effects. The results indicated that 
the 31-40 and 41 to 50 age groups provided for DBM with maximal osteoinductivity and 
this activity started to decline after middle age. This relationship between 
osteoinductivity and age is much like the relationship between bone mass and age, 
although there is no evidence or direct connection between bone mass and 
osteoinductivity of derived DBM. Bone donor source is a critical question. Although this 
study indicated that the middle age donor can provide higher ostoinductive DBM, the 
older donor provided graft materials which induced significant amounts of new bone 
formation and thus provided scientific evidence that more older donors can be recruited 
to enlarge the donor source.
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SUMMARY
In summary, this study established and validated the in vivo and in vitro bioassays 
for the assessment of osteoinductivity of DBM. Further, the study investigated the 
relationships between osteoinductivity and the residual calcium content in the DBM, the 
relationship between the osteoinductivity and particle size, and the relationship between 
the osteoinductivity and donor age and gender. The study validated the biochemical 
assays used for the assessment of the osteoinductivity of DBM. The results provided 
scientific evidence for the standards to be applied to the bone demineralization process 
and donor.
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Statistical Evaluation of the effect of the male donor age on the osteoinductivity of DBM 
(in the in vivo model). Fisher's multiple comparisons. Probability level: 0.05.
'Set 1:51-60,21-30, <202 
Set 2: 21-30, <20,31-40 
Set 3: 41-50
1 Set is a term used in Fisher's multiple comparison. The male age groups which showed no significant difference 
in their osteoinductivity were arranged in the same set. There is a significant difference among the male age 
groups which appear in different sets.
2 This number represents the male donor group tested in the in vivo bioassay.
Appendix B
Statistical Evaluation of the effect of the female donor age on the osteoinductivity of 
DBM (in the in vivo model). Fisher's multiple comparisons. Probability level: 0.05.
'Set 1:21-30, 51-60, <202 
Set 2: 51-60, <20,41-50 
Set 3: 31-40
1 Set is a term used in Fisher's multiple comparison. The female age groups which showed no significant 
difference in their osteoinductivity were arranged in the same set. There is a significant difference among the 
female age groups which appear in different sets.
2 This number represents the fem ale donor group tested in the in vivo bioassay.
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